

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549  
FORM 10-Q**

(Mark One)

**QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934**

**For the quarterly period ended September 28, 2024**

or

**TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934**

**For the transition period from \_\_\_\_\_ to \_\_\_\_\_**

**Commission File Number:** 0-27078

**HENRY SCHEIN, INC.**

(Exact name of registrant as specified in its charter)

**Delaware**  
(State or other jurisdiction of  
incorporation or organization)

**11-3136595**  
(I.R.S. Employer Identification No.)

**135 Duryea Road  
Melville, New York**  
(Address of principal executive offices)  
**11747**  
(Zip Code)

**(631) 843-5500**

(Registrant's telephone number, including area code)

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, par value \$.01 per share	HSIC	The Nasdaq Global Select Market

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.

Yes

No

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).

Yes

No

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company," and "emerging growth company" in Rule 12b-2 of the Exchange Act.

Large accelerated filer

Accelerated filer

Non-accelerated filer

Smaller reporting company

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).

Yes

No

As of October 28, 2024, there were 124,681,294 shares of the registrant's common stock outstanding.

**HENRY SCHEIN, INC.**  
**INDEX**

**PART I. FINANCIAL INFORMATION**

	<b><u>Page</u></b>
<b><u>ITEM 1. Condensed Consolidated Financial Statements:</u></b>	
<u>Condensed Consolidated Balance Sheets as of September 28, 2024 and December 30, 2023</u>	3
<u>Condensed Consolidated Statements of Income for the three and nine months ended September 28, 2024 and September 30, 2023</u>	4
<u>Condensed Consolidated Statements of Comprehensive Income for the three and nine months ended September 28, 2024 and September 30, 2023</u>	5
<u>Condensed Consolidated Statement of Changes in Stockholders' Equity for the three months ended September 28, 2024 and September 30, 2023</u>	6
<u>Condensed Consolidated Statement of Changes in Stockholders' Equity for the nine months ended September 28, 2024 and September 30, 2023</u>	7
<u>Condensed Consolidated Statements of Cash Flows for the nine months ended September 28, 2024 and September 30, 2023</u>	8
<u>Notes to Condensed Consolidated Financial Statements</u>	9
<u>Note 1 – Basis of Presentation</u>	9
<u>Note 2 – Significant Accounting Policies and Recently Issued Accounting Standards</u>	10
<u>Note 3 – Cyber Incident</u>	11
<u>Note 4 – Net Sales from Contracts with Customers</u>	12
<u>Note 5 – Segment Data</u>	13
<u>Note 6 – Business Acquisitions</u>	14
<u>Note 7 – Fair Value Measurements</u>	20
<u>Note 8 – Debt</u>	23
<u>Note 9 – Income Taxes</u>	26
<u>Note 10 – Plans of Restructuring</u>	27
<u>Note 11 – Legal Proceedings</u>	29
<u>Note 12 – Stock-Based Compensation</u>	31
<u>Note 13 – Redeemable Noncontrolling Interests</u>	33
<u>Note 14 – Comprehensive Income</u>	34
<u>Note 15 – Earnings Per Share</u>	35
<u>Note 16 – Supplemental Cash Flow Information</u>	35
<u>Note 17 – Related Party Transactions</u>	36
<b><u>ITEM 2. Management's Discussion and Analysis of Financial Condition and Results of Operations</u></b>	37
<b><u>ITEM 3. Quantitative and Qualitative Disclosures About Market Risk</u></b>	54
<b><u>ITEM 4. Controls and Procedures</u></b>	55
<b><u>PART II. OTHER INFORMATION</u></b>	
<b><u>ITEM 1. Legal Proceedings</u></b>	56
<b><u>ITEM 1A. Risk Factors</u></b>	56
<b><u>ITEM 2. Unregistered Sales of Equity Securities and Use of Proceeds</u></b>	56
<b><u>ITEM 6. Exhibits</u></b>	57
<u>Signature</u>	58

**PART I. FINANCIAL INFORMATION**  
**ITEM 1. CONDENSED CONSOLIDATED FINANCIAL STATEMENTS**  
**HENRY SCHEIN, INC.**  
**CONDENSED CONSOLIDATED BALANCE SHEETS**  
(in millions, except share data)

	September 28, 2024	December 30, 2023
	(unaudited)	
<b>ASSETS</b>		
Current assets:		
Cash and cash equivalents	\$ 126	\$ 171
Accounts receivable, net of allowance for credit losses of \$86 and \$83 (1)	1,660	1,863
Inventories, net	1,754	1,815
Prepaid expenses and other	607	639
Total current assets	4,147	4,488
Property and equipment, net	540	498
Operating lease right-of-use assets	304	325
Goodwill	3,986	3,875
Other intangibles, net	1,100	916
Investments and other	528	471
Total assets	<u>\$ 10,605</u>	<u>\$ 10,573</u>
<b>LIABILITIES, REDEEMABLE NONCONTROLLING INTERESTS AND STOCKHOLDERS' EQUITY</b>		
Current liabilities:		
Accounts payable	\$ 1,026	\$ 1,020
Bank credit lines	638	264
Current maturities of long-term debt	109	150
Operating lease liabilities	77	80
Accrued expenses:		
Payroll and related	289	332
Taxes	159	137
Other	631	700
Total current liabilities	2,929	2,683
Long-term debt (1)	1,906	1,937
Deferred income taxes	123	54
Operating lease liabilities	262	310
Other liabilities	414	436
Total liabilities	5,634	5,420
Redeemable noncontrolling interests	832	864
Commitments and contingencies		
Stockholders' equity:		
Preferred stock, \$0.01 par value, 1,000,000 shares authorized, none outstanding	-	-
Common stock, \$0.01 par value, 480,000,000 shares authorized, 125,154,194 outstanding on September 28, 2024 and 129,247,765 outstanding on December 30, 2023	1	1
Additional paid-in capital	-	-
Retained earnings	3,766	3,860
Accumulated other comprehensive loss	(264)	(206)
Total Henry Schein, Inc. stockholders' equity	3,503	3,655
Noncontrolling interests	636	634
Total stockholders' equity	4,139	4,289
Total liabilities, redeemable noncontrolling interests and stockholders' equity	<u>\$ 10,605</u>	<u>\$ 10,573</u>

- (1) Amounts presented include balances held by our consolidated variable interest entity ("VIE"). At September 28, 2024 and December 30, 2023, includes trade accounts receivable of \$341 million and \$284 million, respectively, and long-term debt of \$210 million and \$210 million, respectively. See [Note 1 – Basis of Presentation](#) for further information.

See accompanying notes.

**HENRY SCHEIN, INC.**  
**CONDENSED CONSOLIDATED STATEMENTS OF INCOME**  
(in millions, except share and per share data)  
(unaudited)

	<b>Three Months Ended</b>		<b>Nine Months Ended</b>	
	<b>September 28, 2024</b>	<b>September 30, 2023</b>	<b>September 28, 2024</b>	<b>September 30, 2023</b>
Net sales	\$ 3,174	\$ 3,162	\$ 9,482	\$ 9,322
Cost of sales	2,181	2,167	6,459	6,386
Gross profit	993	995	3,023	2,936
Operating expenses:				
Selling, general and administrative	724	725	2,296	2,149
Depreciation and amortization	64	59	188	152
Restructuring costs	48	11	73	59
Operating income	157	200	466	576
Other income (expense):				
Interest income	7	6	18	12
Interest expense	(34)	(25)	(96)	(58)
Other, net	(2)	(2)	(1)	(2)
Income before taxes, equity in earnings of affiliates and noncontrolling interests	128	179	387	528
Income taxes	(32)	(39)	(97)	(119)
Equity in earnings of affiliates, net of tax	3	3	12	10
Net income	99	143	302	419
Less: Net income attributable to noncontrolling interests	-	(6)	(6)	(21)
Net income attributable to Henry Schein, Inc.	\$ 99	\$ 137	\$ 296	\$ 398
<b>Earnings per share attributable to Henry Schein, Inc.:</b>				
Basic	\$ 0.79	\$ 1.06	\$ 2.32	\$ 3.04
Diluted	\$ 0.78	\$ 1.05	\$ 2.30	\$ 3.02
<b>Weighted-average common shares outstanding:</b>				
Basic	126,124,715	130,388,353	127,550,045	130,888,717
Diluted	127,054,934	131,442,135	128,498,494	132,149,172

See accompanying notes.

**HENRY SCHEIN, INC.**  
**CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME**  
**(in millions)**  
**(unaudited)**

	<u>Three Months Ended</u>		<u>Nine Months Ended</u>	
	<u>September 28,</u> <u>2024</u>	<u>September 30,</u> <u>2023</u>	<u>September 28,</u> <u>2024</u>	<u>September 30,</u> <u>2023</u>
Net income	\$ 99	\$ 143	\$ 302	\$ 419
Other comprehensive income (loss), net of tax:				
Foreign currency translation gain (loss)	58	(45)	(58)	(17)
Unrealized gain (loss) from hedging activities	(18)	6	(3)	2
Other comprehensive income (loss), net of tax	40	(39)	(61)	(15)
Comprehensive income	139	104	241	404
Comprehensive income attributable to noncontrolling interests:				
Net income	-	(6)	(6)	(21)
Foreign currency translation loss (gain)	(12)	2	3	1
Comprehensive income attributable to noncontrolling interests	(12)	(4)	(3)	(20)
Comprehensive income attributable to Henry Schein, Inc.	<u>\$ 127</u>	<u>\$ 100</u>	<u>\$ 238</u>	<u>\$ 384</u>

See accompanying notes.

**HENRY SCHEIN, INC.**  
**CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN**  
**STOCKHOLDERS' EQUITY**  
**(in millions, except share data)**  
**(unaudited)**

	Common Stock		Additional Paid-in Capital	Retained Earnings	Accumulated Other		Noncontrolling Interests	Total Stockholders' Equity
	\$0.01 Par Value				Income / (Loss)			
	Shares	Amount						
Balance, June 29, 2024	127,080,545	\$ 1	\$ -	\$ 3,803	\$ (292)	\$ 636	\$ 4,148	
Net income (loss) (excluding \$ 1 attributable to Redeemable noncontrolling interests)	-	-	-	99	-	(1)	98	
Foreign currency translation gain (excluding gain of \$ 11 attributable to Redeemable noncontrolling interests)	-	-	-	-	46	1	47	
Unrealized loss from hedging activities, net of tax benefit of \$ 7	-	-	-	-	(18)	-	(18)	
Purchase of noncontrolling interests	-	-	(1)	-	-	(1)	(2)	
Change in fair value of redeemable securities	-	-	(6)	-	-	-	(6)	
Noncontrolling interests and adjustments related to business acquisitions	-	-	(4)	-	-	1	(3)	
Repurchase and retirement of common stock	(1,954,076)	-	(18)	(119)	-	-	(137)	
Stock issued upon exercise of stock options	22,448	-	1	-	-	-	1	
Stock-based compensation expense	7,655	-	10	-	-	-	10	
Shares withheld for payroll taxes	(2,403)	-	-	-	-	-	-	
Settlement of stock-based compensation awards	25	-	1	-	-	-	1	
Transfer of charges in excess of capital	-	-	17	(17)	-	-	-	
Balance, September 28, 2024	125,154,194	\$ 1	\$ -	\$ 3,766	\$ (264)	\$ 636	\$ 4,139	

	Common Stock		Additional Paid-in Capital	Retained Earnings	Accumulated Other		Noncontrolling Interests	Total Stockholders' Equity
	\$0.01 Par Value				Income / (Loss)			
	Shares	Amount						
Balance, July 1, 2023	130,576,806	\$ 1	\$ -	\$ 3,769	\$ (210)	\$ 626	\$ 4,186	
Net income (excluding \$ 2 attributable to Redeemable noncontrolling interests)	-	-	-	137	-	4	141	
Foreign currency translation loss (excluding loss of \$ 2 attributable to Redeemable noncontrolling interests)	-	-	-	-	(43)	-	(43)	
Unrealized gain from hedging activities, net of tax of \$ 3	-	-	-	-	6	-	6	
Distributions to noncontrolling shareholders	-	-	-	-	-	(1)	(1)	
Change in fair value of redeemable securities	-	-	28	-	-	-	28	
Noncontrolling interests and adjustments related to business acquisitions	-	-	(1)	-	-	-	(1)	
Repurchases and retirement of common stock	(659,681)	-	(6)	(44)	-	-	(50)	
Stock-based compensation expense	23,985	-	14	-	-	-	14	
Stock issued upon exercise of stock options	3,884	-	-	-	-	-	-	
Shares withheld for payroll taxes	(9,183)	-	-	-	-	-	-	
Settlement of stock-based compensation awards	72	-	-	-	-	-	-	
Transfer of charges in excess of capital	-	-	(35)	35	-	-	-	
Balance, September 30, 2023	129,935,883	\$ 1	\$ -	\$ 3,897	\$ (247)	\$ 629	\$ 4,280	

See accompanying notes.

**HENRY SCHEIN, INC.**  
**CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN**  
**STOCKHOLDERS' EQUITY**  
**(in millions, except share data)**  
**(unaudited)**

	Common Stock		Additional Paid-in Capital	Retained Earnings	Accumulated Other Comprehensive		Noncontrolling Interests	Total Stockholders' Equity
	\$.01 Par Value				Income / (Loss)			
	Shares	Amount						
Balance, December 30, 2023	129,247,765	\$ 1	\$ -	\$ 3,860	\$ (206)	\$ 634	\$ 4,289	
Net income (excluding loss of \$0 attributable to Redeemable noncontrolling interests)	-	-	-	296	-	6	302	
Foreign currency translation gain/(loss) (excluding loss of \$4 attributable to Redeemable noncontrolling interests)	-	-	-	-	(55)	1	(54)	
Unrealized loss from hedging activities, net of tax benefit of \$1	-	-	-	-	(3)	-	(3)	
Distributions to noncontrolling shareholders	-	-	-	-	-	(5)	(5)	
Purchase of noncontrolling interests	-	-	(7)	-	-	(1)	(8)	
Change in fair value of redeemable securities	-	-	(87)	-	-	-	(87)	
Noncontrolling interests and adjustments related to business acquisitions	-	-	(8)	-	-	1	(7)	
Repurchase and retirement of common stock	(4,368,510)	-	(42)	(271)	-	-	(313)	
Stock issued upon exercise of stock options	47,688	-	3	-	-	-	3	
Stock-based compensation expense	337,753	-	30	-	-	-	30	
Shares withheld for payroll taxes	(110,566)	-	(9)	-	-	-	(9)	
Settlement of stock-based compensation awards	64	-	1	-	-	-	1	
Transfer of charges in excess of capital	-	-	119	(119)	-	-	-	
Balance, September 28, 2024	125,154,194	\$ 1	\$ -	\$ 3,766	\$ (264)	\$ 636	\$ 4,139	

	Common Stock		Additional Paid-in Capital	Retained Earnings	Accumulated Other Comprehensive		Noncontrolling Interests	Total Stockholders' Equity
	\$.01 Par Value				Income / (Loss)			
	Shares	Amount						
Balance, December 31, 2022	131,792,817	\$ 1	\$ -	\$ 3,678	\$ (233)	\$ 649	\$ 4,095	
Net income (excluding \$11 attributable to Redeemable noncontrolling interests)	-	-	-	398	-	10	408	
Foreign currency translation loss (excluding loss of \$1 attributable to Redeemable noncontrolling interests)	-	-	-	-	(16)	-	(16)	
Unrealized gain from hedging activities, net of tax of \$1	-	-	-	-	2	-	2	
Distributions to noncontrolling shareholders	-	-	-	-	-	(28)	(28)	
Change in fair value of redeemable securities	-	-	14	-	-	-	14	
Noncontrolling interests and adjustments related to business acquisitions	-	-	-	-	-	(2)	(2)	
Repurchases and retirement of common stock	(2,521,695)	-	(26)	(175)	-	-	(201)	
Stock-based compensation expense	1,060,883	-	38	-	-	-	38	
Stock issued upon exercise of stock options	19,744	-	1	-	-	-	1	
Shares withheld for payroll taxes	(415,048)	-	(32)	-	-	-	(32)	
Settlement of stock-based compensation awards	(818)	-	1	-	-	-	1	
Transfer of charges in excess of capital	-	-	4	(4)	-	-	-	
Balance, September 30, 2023	129,935,883	\$ 1	\$ -	\$ 3,897	\$ (247)	\$ 629	\$ 4,280	

See accompanying notes.

**HENRY SCHEIN, INC.**  
**CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS**  
(in millions)  
(unaudited)

	Nine Months Ended	
	September 28, 2024	September 30, 2023
<b>Cash flows from operating activities:</b>		
Net income	\$ 302	\$ 419
Adjustments to reconcile net income to net cash provided by operating activities:		
Depreciation and amortization	221	180
Non-cash restructuring charges	11	13
Stock-based compensation expense	30	38
Provision for losses on trade and other accounts receivable	12	7
Benefit from deferred income taxes	(41)	(4)
Equity in earnings of affiliates	(12)	(10)
Distributions from equity affiliates	10	12
Changes in unrecognized tax benefits	3	5
Other	(25)	(11)
Changes in operating assets and liabilities, net of acquisitions:		
Accounts receivable	188	(72)
Inventories	38	180
Other current assets	38	(55)
Accounts payable and accrued expenses	(131)	(170)
Net cash provided by operating activities	<u>644</u>	<u>532</u>
<b>Cash flows from investing activities:</b>		
Purchases of property and equipment	(112)	(108)
Payments related to equity investments and business acquisitions, net of cash acquired	(223)	(668)
Proceeds from loan to affiliate	3	4
Capitalized software costs	(30)	(30)
Other	(10)	(6)
Net cash used in investing activities	<u>(372)</u>	<u>(808)</u>
<b>Cash flows from financing activities:</b>		
Net change in bank credit lines	374	(98)
Proceeds from issuance of long-term debt	120	1,158
Principal payments for long-term debt	(193)	(457)
Debt issuance costs	-	(3)
Proceeds from issuance of stock upon exercise of stock options	3	1
Payments for repurchases and retirement of common stock	(310)	(200)
Payments for taxes related to shares withheld for employee taxes	(9)	(34)
Distributions to noncontrolling shareholders	(36)	(41)
Acquisitions of noncontrolling interests in subsidiaries	(255)	(19)
Net cash provided by (used in) financing activities	<u>(306)</u>	<u>307</u>
Effect of exchange rate changes on cash and cash equivalents	(11)	18
Net change in cash and cash equivalents	(45)	49
Cash and cash equivalents, beginning of period	171	117
Cash and cash equivalents, end of period	<u>\$ 126</u>	<u>\$ 166</u>

See accompanying notes.



**HENRY SCHEIN, INC.**  
**NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS**  
**(in millions, except share and per share data)**  
**(unaudited)**

**Note 1 – Basis of Presentation**

Our condensed consolidated financial statements include the accounts of Henry Schein, Inc., and all of our controlled subsidiaries (“we”, “us” and “our”). All intercompany accounts and transactions are eliminated in consolidation. Investments in unconsolidated affiliates for which we have the ability to influence the operating or financial decisions are accounted for under the equity method. Certain prior period amounts have been reclassified to conform to the current period presentation. These reclassifications, individually and in the aggregate, did not have a material impact on our condensed consolidated financial condition, results of operations or cash flows.

Our accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States (“U.S. GAAP”) for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information and footnote disclosures required by U.S. GAAP for complete financial statements.

The unaudited interim condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes to the consolidated financial statements contained in our Annual Report on Form 10-K for the year ended December 30, 2023 and with the information contained in our other publicly-available filings with the Securities and Exchange Commission. The condensed consolidated financial statements reflect all adjustments considered necessary for a fair presentation of the consolidated results of operations and financial position for the interim periods presented. All such adjustments are of a normal recurring nature.

The preparation of financial statements in conformity with accounting principles generally accepted in the United States requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. The results of operations for the three and nine months ended September 28, 2024 are not necessarily indicative of the results to be expected for any other interim period or for the year ending December 28, 2024.

Our condensed consolidated financial statements reflect estimates and assumptions made by us that affect, among other things, our goodwill, long-lived asset and definite-lived intangible asset valuation; inventory valuation; equity investment valuation; assessment of the annual effective tax rate; valuation of deferred income taxes and income tax contingencies; the allowance for credit losses; hedging activity; supplier rebates; measurement of compensation cost for certain share-based performance awards and cash bonus plans; and pension plan assumptions.

We consolidate the results of operations and financial position of a trade accounts receivable securitization which we consider a VIE because we are its primary beneficiary, as we have the power to direct activities that most significantly affect its economic performance and have the obligation to absorb the majority of its losses or benefits. For this VIE, the trade accounts receivable transferred to the VIE are pledged as collateral to the related debt. The VIE’s creditors have recourse to us for losses on these trade accounts receivable. At September 28, 2024 and December 30, 2023, certain trade accounts receivable that can only be used to settle obligations of this VIE were \$341 million and \$284 million, respectively, and the liabilities of this VIE where the creditors have recourse to us were \$210 million and \$210 million, respectively.

**HENRY SCHEIN, INC.**  
**NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS**  
**(in millions, except share and per share data)**  
**(unaudited)**

**Note 2 – Significant Accounting Policies and Recently Issued Accounting Standards**

**Significant Accounting Policies**

There have been no material changes in our significant accounting policies during the three and nine months ended September 28, 2024, as compared to the significant accounting policies described in Item 8 of our Annual Report on Form 10-K for the year ended December 30, 2023.

**Recently Issued Accounting Standards**

In March 2024, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2024-01, “*Compensation - Stock Compensation (Topic 718): Scope Application of Profits Interest and Similar Awards*,” which clarifies how to determine whether profits interest and similar awards should be accounted for as a share-based payment arrangement under Topic 718 or within the scope of other guidance. The ASU provides an illustrative example with multiple fact patterns and amends the structure of paragraph 718-10-15-3 of Topic 718 to improve its clarity and operability. The guidance in ASU 2024-01 applies to all entities that issue profits interest awards as compensation to employees or nonemployees in exchange for goods or services. Entities can apply the amendments either retrospectively to all periods presented in the financial statements or prospectively to profits interest awards granted or modified on or after the date of adoption. If prospective application is elected, an entity must disclose the nature of and reason for the change in accounting principle that resulted from the adoption of the ASU. This ASU is effective for fiscal years beginning after December 15, 2024, including interim periods within those fiscal years. We do not expect that the requirements of ASU 2024 – 01 will have a material impact on our consolidated financial statements.

In December 2023, FASB issued ASU 2023-09, “*Income Taxes (Topic 740): Improvements to Income Tax Disclosures*,” which requires public business entities to disclose additional information in specified categories with respect to the reconciliation of the effective tax rate to the statutory rate for federal, state and foreign income taxes. It also requires greater detail about individual reconciling items in the rate reconciliation to the extent the impact of those items exceeds a specified threshold. In addition to new disclosures associated with the rate reconciliation, the ASU requires information pertaining to taxes paid (net of refunds received) to be disaggregated for federal, state and foreign taxes and further disaggregated for specific jurisdictions to the extent the related amounts exceed a quantitative threshold. The ASU also describes items that need to be disaggregated based on their nature, which is determined by reference to the item’s fundamental or essential characteristics, such as the transaction or event that triggered the establishment of the reconciling item and the activity with which the reconciling item is associated. The ASU eliminates the historic requirement that entities disclose information concerning unrecognized tax benefits having a reasonable possibility of significantly increasing or decreasing in the 12 months following the reporting date. This ASU is effective for annual periods beginning after December 15, 2024. Early adoption is permitted for annual financial statements that have not yet been issued or made available for issuance. This ASU should be applied on a prospective basis; however, retrospective application is permitted. We are currently evaluating the impact that ASU 2023-09 will have on our consolidated financial statements.

In November 2023, the FASB issued ASU 2023-07, “*Segment Reporting (Topic 280): Improvements to Reportable Segments*,” which aims to improve financial reporting by requiring disclosure of incremental segment information on an annual and interim basis for all public entities to enable investors to develop more decision-useful financial analyses. Currently, Topic 280 requires that a public entity disclose certain information about its reportable segments. For example, a public entity is required to report a measure of segment profit or loss that the chief operating decision maker uses to assess segment performance and make decisions about allocating resources. Topic 280 also requires other specified segment items and amounts, such as depreciation, amortization and depletion expense, to be disclosed under certain circumstances. The amendments in this ASU do not change or remove those disclosure requirements and do not change how a public entity identifies its operating segments,

**HENRY SCHEIN, INC.**  
**NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS**  
**(in millions, except share and per share data)**  
**(unaudited)**

aggregates those operating segments or applies the quantitative thresholds to determine its reportable segments. This ASU is effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024. Early adoption is permitted. We are currently evaluating the impact that ASU 2023- 07 will have on our consolidated financial statements.

**Note 3 – Cyber Incident**

In October 2023 Henry Schein experienced a cyber incident that primarily affected the operations of our North American and European dental and medical distribution businesses. Henry Schein One, our practice management software, revenue cycle management and patient relationship management solutions business, was not affected, and our manufacturing businesses were mostly unaffected. On November 22, 2023, we experienced a disruption of our ecommerce platform and related applications, which was remediated.

During the three and nine months ended September 28, 2024, we had a sales decrease in our dental and medical distribution businesses, which we believe was primarily a result of lower sales to episodic customers following last year's cyber incident.

During the three and nine months ended September 28, 2024, we incurred \$1 million and \$9 million, respectively, of expenses directly related to the cyber incident, mostly consisting of professional fees. We maintain cyber insurance, subject to certain retentions and policy limitations. With respect to the October 2023 cyber incident, we have a \$60 million insurance policy, following a \$5 million retention. During the three and nine months ended September 28, 2024, we received insurance proceeds of \$10 million and \$20 million, respectively, representing a partial insurance recovery of losses related to the cyber incident. The expenses and insurance recoveries related to the cyber incident are included in the selling, general and administrative line in our condensed consolidated statements of income.

**HENRY SCHEIN, INC.**  
**NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS**  
(in millions, except share and per share data)  
(unaudited)

**Note 4 – Net Sales from Contracts with Customers**

Net sales are recognized in accordance with policies disclosed in Item 8 of our Annual Report on Form 10-K for the year ended December 30, 2023.

*Disaggregation of Net Sales*

The following table disaggregates our net sales by reportable and operating segment and geographic area:

	Three Months Ended September 28, 2024			Nine Months Ended September 28, 2024		
	North America	International	Global	North America	International	Global
	<b>Net sales:</b>					
Health care distribution						
Dental	\$ 1,089	\$ 763	\$ 1,852	\$ 3,321	\$ 2,369	\$ 5,690
Medical	1,076	25	1,101	3,060	80	3,140
Total health care distribution	2,165	788	2,953	6,381	2,449	8,830
Technology and value-added services	190	31	221	565	87	652
Total net sales	<u>\$ 2,355</u>	<u>\$ 819</u>	<u>\$ 3,174</u>	<u>\$ 6,946</u>	<u>\$ 2,536</u>	<u>\$ 9,482</u>

	Three Months Ended September 30, 2023			Nine Months Ended September 30, 2023		
	North America	International	Global	North America	International	Global
	<b>Net sales:</b>					
Health care distribution						
Dental	\$ 1,134	\$ 748	\$ 1,882	\$ 3,447	\$ 2,290	\$ 5,737
Medical	1,044	26	1,070	2,920	71	2,991
Total health care distribution	2,178	774	2,952	6,367	2,361	8,728
Technology and value-added services	185	25	210	519	75	594
Total net sales	<u>\$ 2,363</u>	<u>\$ 799</u>	<u>\$ 3,162</u>	<u>\$ 6,886</u>	<u>\$ 2,436</u>	<u>\$ 9,322</u>

*Contract Liabilities*

At September 28, 2024, December 30, 2023, and December 31, 2022, the current and non-current contract liabilities were \$76 million and \$8 million; \$89 million and \$9 million; and \$86 million and \$8 million, respectively. During the nine months ended September 28, 2024, we recognized, in net sales, \$72 million of the amount that was previously deferred at December 30, 2023. During the nine months ended September 30, 2023, we recognized in net sales \$70 million of the amount that was previously deferred at December 31, 2022. Current contract liabilities are included in accrued expenses: other and the non-current contract liabilities are included in other liabilities within our consolidated balance sheets.

**HENRY SCHEIN, INC.**  
**NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS**  
**(in millions, except share and per share data)**  
**(unaudited)**

**Note 5 – Segment Data**

We conduct our business through two reportable segments: (i) health care distribution and (ii) technology and value-added services. These segments offer different products and services to the same customer base. Our global dental businesses serve office-based dental practitioners, dental laboratories, schools, government and other institutions. Our medical businesses serve physician offices, urgent care centers, ambulatory care sites, emergency medical technicians, dialysis centers, home health, federal and state governments and large enterprises, such as group practices, and integrated delivery networks, among other providers across a wide range of specialties. Our dental and medical groups serve practitioners in 33 countries worldwide.

The health care distribution reportable segment aggregates our global dental and medical operating segments. This segment distributes consumable products, dental specialty products (including implant, orthodontic and endodontic products), small equipment, laboratory products, large equipment, equipment repair services, branded and generic pharmaceuticals, vaccines, surgical products, diagnostic tests, infection-control products, personal protective equipment (“PPE”) products, vitamins and orthopedic implants.

Our global technology and value-added services reportable segment provides software, technology and other value-added services to health care practitioners. Our technology offerings include practice management software systems for dental practitioners. Our value-added practice solutions include practice consultancy, education, revenue cycle management and financial services on a non-recourse basis, e-services, continuing education services for practitioners, practice technology, network and hardware services, and other services.

The following tables present information about our reportable and operating segments:

	<b>Three Months Ended</b>		<b>Nine Months Ended</b>	
	<b>September 28, 2024</b>	<b>September 30, 2023</b>	<b>September 28, 2024</b>	<b>September 30, 2023</b>
<b>Net sales:</b>				
Health care distribution <sup>(1)</sup>				
Dental	\$ 1,852	\$ 1,882	\$ 5,690	\$ 5,737
Medical	1,101	1,070	3,140	2,991
Total health care distribution	2,953	2,952	8,830	8,728
Technology and value-added services <sup>(2)</sup>	221	210	652	594
Total	<u>\$ 3,174</u>	<u>\$ 3,162</u>	<u>\$ 9,482</u>	<u>\$ 9,322</u>

- (1) Consists of consumable products, dental specialty products (including implant, orthodontic and endodontic products), small equipment, laboratory products, large equipment, equipment repair services, branded and generic pharmaceuticals, vaccines, surgical products, diagnostic tests, infection-control products, PPE products, vitamins and orthopedic implants.
- (2) Consists of practice management software and other value-added products, which are distributed primarily to health care providers, practice consultancy, education, revenue cycle management and financial services on a non-recourse basis, e-services, continuing education services for practitioners, practice technology, network and hardware services, and other services.

	<b>Three Months Ended</b>		<b>Nine Months Ended</b>	
	<b>September 28, 2024</b>	<b>September 30, 2023</b>	<b>September 28, 2024</b>	<b>September 30, 2023</b>
<b>Operating Income:</b>				
Health care distribution	\$ 118	\$ 160	\$ 390	\$ 471
Technology and value-added services	39	40	76	105
Total	<u>\$ 157</u>	<u>\$ 200</u>	<u>\$ 466</u>	<u>\$ 576</u>

**HENRY SCHEIN, INC.**  
**NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS**  
**(in millions, except share and per share data)**  
**(unaudited)**

**Note 6 – Business Acquisitions**

Our acquisition strategy is focused on investments in companies that add new customers and sales teams, increase our geographic footprint (whether entering a new country, such as emerging markets, or building scale where we have already invested in businesses), and finally, those that enable us to access new products and technologies.

*Acquisition of TriMed*

On April 1, 2024, we acquired a 60% voting equity interest in TriMed Inc. (“TriMed”), a global developer of solutions for the orthopedic treatment of lower and upper extremities, headquartered in California.

The following table aggregates the preliminary estimated fair value, as of the date of acquisition, of consideration paid and net assets acquired in the TriMed acquisition:

	<u>2024</u>
Acquisition consideration:	
Cash	\$ 141
Deferred consideration	22
Redeemable noncontrolling interests	153
Total consideration	<u>\$ 316</u>
Identifiable assets acquired and liabilities assumed:	
Current assets	\$ 36
Intangible assets	221
Other noncurrent assets	10
Current liabilities	(9)
Deferred income taxes	(62)
Other noncurrent liabilities	(6)
Total identifiable net assets	<u>190</u>
Goodwill	126
Total net assets acquired	<u>\$ 316</u>

Goodwill is a result of synergies that are expected to originate from the acquisition as well as the expected growth potential of TriMed. The acquired goodwill is not deductible for tax purposes.

The following table summarizes the identifiable intangible assets acquired as part of the acquisition of TriMed:

	<u>2024</u>	<u>Weighted Average Useful Lives (in years)</u>
Product development	\$ 204	9
Trademarks / Tradenames	9	7
In process research & development	8	Not Applicable
Total	<u>\$ 221</u>	

Except for in-process research and development (“IPR&D”), intangible assets acquired as a result of the TriMed acquisition are being amortized over their estimated useful lives using the straight-line method of amortization. The IPR&D is accounted for as an indefinite-lived intangible asset and is not amortized until completion or abandonment of the associated research and development efforts. IPR&D is tested for impairment annually or periodically if an indicator of impairment exists during the period until completion.

**HENRY SCHEIN, INC.**  
**NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS**  
**(in millions, except share and per share data)**  
**(unaudited)**

The accounting for the acquisition of TriMed has not been completed in several areas, including but not limited to pending assessments of accounts receivable, right-of-use lease assets, accrued liabilities, lease liabilities, income and non-income based taxes. During the three months ended September 28, 2024, we did not record any material measurement period adjustments. We expect to finalize these amounts as soon as possible but no later than one year from the acquisition date.

Pro forma financial information has not been presented because the impact of the TriMed acquisition during the three and nine months ended September 28, 2024 was immaterial to our condensed consolidated financial statements.

*Other 2024 Acquisitions*

During the nine months ended September 28, 2024, we acquired companies within the health care distribution and technology and value-added services segments. Our acquired ownership interest in these companies range from 51% to 100%. Total consideration for these acquisitions was \$113 million. Net assets acquired primarily consisted of \$59 million of goodwill and \$64 million of intangible assets. The intangible assets acquired consisted of customer relationships and lists of \$33 million, trademarks and tradenames of \$24 million, product development of \$5 million and non-compete agreements of \$2 million. Weighted average useful lives for these acquired intangible assets were 11 years, 7 years, 9 years and 5 years, respectively.

During the nine months ended September 28, 2024, we completed the accounting for certain acquisitions that occurred in fiscal year 2024 and we did not record any material measurement period adjustments related to these acquisitions. The accounting for other acquisitions in fiscal year 2024 has not been completed in several areas, including but not limited to pending assessment of accounts receivable, right-of-use lease assets, lease liabilities, accrued liabilities and non-income based taxes.

Goodwill is a result of the synergies and cross-selling opportunities that these acquisitions are expected to provide for us, as well as the expected growth potential. The majority of the acquired goodwill is not deductible for tax purposes.

During the three and nine months ended September 28, 2024, in connection with an acquisition of a controlling interest of an affiliate, we recognized a gain of approximately \$19 million related to the remeasurement to fair value of our previously held equity investment, using a discounted cash flow model based on Level 3 inputs, as defined in [Note 7 – Fair Value Measurements](#), which was recorded in selling, general and administrative in the condensed consolidated statements of income.

The impact of these acquisitions, individually and in the aggregate, was not considered material to our condensed consolidated financial statements.

**HENRY SCHEIN, INC.**  
**NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS**  
**(in millions, except share and per share data)**  
**(unaudited)**

### 2023 Acquisitions

#### Acquisition of Shield Healthcare

On October 2, 2023, we acquired a 90% voting equity interest in Shield Healthcare, Inc. (“Shield”), a supplier of homecare medical products delivered directly to patients in their homes, for consideration of \$348 million (including cash paid of \$289 million, deferred consideration of \$22 million and redeemable noncontrolling interests of \$37 million). Shield expands our existing medical business by delivering a diverse range of products, including items such as incontinence, urology, ostomy, enteral nutrition, advanced wound care and diabetes supplies. Additionally, Shield offers continuous glucose monitoring devices directly to patients in their homes.

During the quarter ended June 29, 2024, we completed the accounting for our acquisition of Shield. The following table aggregates the final fair value, as of the date of the acquisition, of consideration paid and net assets acquired in the Shield acquisition:

	<b>Final Allocation</b>
Acquisition consideration:	
Cash	\$ 289
Deferred consideration	22
Redeemable noncontrolling interests	37
Total consideration	<u>\$ 348</u>
Identifiable assets acquired and liabilities assumed:	
Current assets	\$ 41
Intangible assets	166
Other noncurrent assets	16
Current liabilities	(24)
Deferred income taxes	(43)
Other noncurrent liabilities	(7)
Total identifiable net assets	<u>149</u>
Goodwill	199
Total net assets acquired	<u>\$ 348</u>

Goodwill is a result of synergies that are expected to originate from the acquisition as well as the expected growth potential of Shield. The acquired goodwill is not deductible for tax purposes.

The following table summarizes the identifiable intangible assets acquired as part of the acquisition of Shield:

	<b>2023</b>	Weighted Average Useful Lives (in years)
Customer relationships and lists	\$ 156	12
Trademarks / Tradenames	10	5
Total	<u>\$ 166</u>	

Pro forma financial information has not been presented because the impact of the Shield acquisition was immaterial to our consolidated financial statements.



**HENRY SCHEIN, INC.**  
**NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS**  
**(in millions, except share and per share data)**  
**(unaudited)**

*Acquisition of S.I.N. Implant System*

On July 5, 2023, we acquired a 100% voting equity interest in S.I.N. Implant System (“S.I.N.”) for consideration of \$329 million. Based in São Paulo, S.I.N. manufactures an extensive line of products to perform dental implant procedures and is focused on advancing the development of value-priced dental implants. In 2023, S.I.N. expanded the distribution of its products into the United States and other international markets.

During the quarter ended June 29, 2024, we completed the accounting for our acquisition of S.I.N. The following table aggregates the final fair value, as of the date of acquisition, of consideration paid and net assets acquired in the S.I.N. acquisition:

	<b>Final Allocation</b>
Acquisition consideration:	
Cash	\$ 329
Total consideration	<u>\$ 329</u>
Identifiable assets acquired and liabilities assumed:	
Current assets	\$ 73
Intangible assets	87
Other noncurrent assets	48
Current liabilities	(33)
Long-term debt	(22)
Deferred income taxes	(38)
Other noncurrent liabilities	(27)
Total identifiable net assets	88
Goodwill	241
Total net assets acquired	<u>\$ 329</u>

Goodwill is a result of synergies that are expected to originate from the acquisition as well as the expected growth potential of S.I.N. The acquired goodwill is not deductible for tax purposes.

The following table summarizes the identifiable intangible assets acquired as part of the acquisition of S.I.N.:

	<b>2023</b>	Weighted Average Useful Lives (in years)
Customer relationships and lists	\$ 38	7
Product development	36	8
Trademarks / Tradenames	13	10
Total	<u>\$ 87</u>	

Pro forma financial information has not been presented because the impact of the S.I.N. acquisition was immaterial to our consolidated financial statements.

**HENRY SCHEIN, INC.**  
**NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS**  
**(in millions, except share and per share data)**  
**(unaudited)**

*Acquisition of Biotech Dental*

On April 5, 2023, we acquired a 57% voting equity interest in Biotech Dental, a provider of dental implants, clear aligners, individualized prosthetics and innovative digital dental software based in France, for preliminary consideration of \$423 million (including cash paid of \$216 million, \$25 million of contributed equity share in a controlled subsidiary, and redeemable noncontrolling interests of \$182 million). Biotech Dental has several important solutions for dental practices and dental labs, including Nemotec, a comprehensive, integrated suite of planning and diagnostic software using open architecture that connects disparate medical devices to create a digital view of the patient, offering greater diagnostic accuracy and an improved patient experience.

During the quarter ended March 30, 2024, we completed the accounting for our acquisition of Biotech Dental. The following table aggregates the final fair value, as of the date of acquisition, of consideration paid and net assets acquired in the Biotech Dental acquisition:

	<b>Final Allocation</b>
Acquisition consideration:	
Cash	\$ 216
Fair value of contributed equity share in a controlled subsidiary	25
Redeemable noncontrolling interests	182
Total consideration	<u>\$ 423</u>
Identifiable assets acquired and liabilities assumed:	
Current assets	\$ 74
Intangible assets	189
Other noncurrent assets	69
Current liabilities	(60)
Long-term debt	(73)
Deferred income taxes	(53)
Other noncurrent liabilities	(20)
Total identifiable net assets	126
Goodwill	297
Total net assets acquired	<u>\$ 423</u>

Goodwill is a result of synergies that are expected to originate from the acquisition as well as the expected growth potential of Biotech Dental. The acquired goodwill is not deductible for tax purposes.

The following table summarizes the identifiable intangible assets acquired as part of the acquisition of Biotech Dental:

	<b>2023</b>	Weighted Average Useful Lives (in years)
Product development	\$ 124	10
Customer relationships and lists	47	9
Trademarks / Tradenames	18	7
Total	<u>\$ 189</u>	

Pro forma financial information has not been presented because the impact of the Biotech Dental acquisition was immaterial to our condensed consolidated financial statements.

**HENRY SCHEIN, INC.**  
**NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS**  
**(in millions, except share and per share data)**  
**(unaudited)**

*Other 2023 Acquisitions*

During the year ended December 30, 2023, in addition to those noted above, we acquired companies within the health care distribution and technology and value-added services segments. Our acquired ownership interest ranged between 51% to 100%. During the three and nine months ended September 28, 2024, we recorded an adjustment of \$0 million and \$38 million, respectively, within selling, general and administrative in our condensed consolidated statements of income, representing a change in the fair value of contingent consideration related to a 2023 acquisition.

During the nine months ended September 28, 2024, we completed the accounting for certain fiscal year 2023 acquisitions. In relation to these acquisitions, we did not record material adjustments in our condensed consolidated financial statements relating to changes in estimated values of assets acquired, liabilities assumed and contingent consideration assets and liabilities.

Goodwill is a result of the synergies and cross-selling opportunities that these acquisitions are expected to provide for us, as well as the expected growth potential. The majority of the acquired goodwill is deductible for tax purposes.

Pro forma financial information for our 2023 acquisitions has not been presented because the impact of the acquisitions was immaterial to our condensed consolidated financial statements.

*Acquisition Costs*

During the three and nine months ended September 28, 2024, we incurred \$2 million and \$5 million in acquisition costs, respectively. During the three and nine months ended September 30, 2023, we incurred \$6 million and \$18 million in acquisition costs, respectively. These costs are included in selling, general and administrative in our condensed consolidated statements of income.

**HENRY SCHEIN, INC.**  
**NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS**  
**(in millions, except share and per share data)**  
**(unaudited)**

**Note 7 – Fair Value Measurements**

Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The fair value hierarchy distinguishes between (1) market participant assumptions developed based on market data obtained from independent sources (observable inputs) and (2) an entity's own assumptions about market participant assumptions developed based on the best information available in the circumstances (unobservable inputs).

The fair value hierarchy consists of three broad levels, which gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1) and the lowest priority to unobservable inputs (Level 3). The three levels of the fair value hierarchy are described as follows:

- Level 1— Unadjusted quoted prices in active markets for identical assets or liabilities that are accessible at the measurement date.
- Level 2— Inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly. Level 2 inputs include: quoted prices for similar assets or liabilities in active markets; quoted prices for identical or similar assets or liabilities in markets that are not active; inputs other than quoted prices that are observable for the asset or liability; and inputs that are derived principally from or corroborated by observable market data by correlation or other means.
- Level 3— Inputs that are unobservable for the asset or liability.

The following section describes the fair values of our financial instruments and the methodologies that we used to measure their fair values.

*Investments and notes receivable*

There are no quoted market prices available for investments in unconsolidated affiliates and notes receivable. Certain of our notes receivable contain variable interest rates. We believe the carrying amounts are a reasonable estimate of fair value based on the interest rates in the applicable markets. Our investments and notes receivable fair value is based on Level 3 inputs within the fair value hierarchy.

*Debt*

The fair value of our debt (including bank credit lines, current maturities of long-term debt and long-term debt) is based on Level 3 inputs within the fair value hierarchy, and as of September 28, 2024 and December 30, 2023 was estimated at \$2,653 million and \$2,351 million, respectively. Factors that we considered when estimating the fair value of our debt include market conditions, such as interest rates and credit spreads.

*Derivative contracts*

Derivative contracts are valued using quoted market prices and significant other observable inputs. Our derivative instruments primarily include foreign currency forward agreements, forecasted inventory purchase commitments, foreign currency forward contracts, interest rate swaps and total return swaps.

The fair values for the majority of our foreign currency derivative contracts are obtained by comparing our contract rate to a published forward price of the underlying market rates, which are based on market rates for comparable transactions that are classified within Level 2 of the fair value hierarchy.

**HENRY SCHEIN, INC.**  
**NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS**  
**(in millions, except share and per share data)**  
**(unaudited)**

The fair value of the interest rate swap, which is classified within Level 2 of the fair value hierarchy, is determined by comparing our contract rate to a forward market rate as of the valuation date.

The fair value of total return swaps is determined by valuing the underlying exchange traded funds of the swap using market-on-close pricing by industry providers as of the valuation date that are classified within Level 2 of the fair value hierarchy.

*Redeemable noncontrolling interests*

The values for redeemable noncontrolling interests are based on recent transactions and/or implied multiples of earnings that are classified within Level 3 of the fair value hierarchy. See [Note 13 – Redeemable Noncontrolling Interests](#) for additional information.

*Intangible Assets*

Assets measured on a non-recurring basis at fair value include intangibles. Inputs for measuring intangibles are classified as Level 3 within the fair value hierarchy.

*Contingent Consideration*

We estimate the fair value of contingent consideration payments as part of the acquisition price and record the estimated fair value of contingent consideration as a liability on our condensed consolidated balance sheet. For transactions accounted for as business combinations, subsequent changes in the estimated fair value of contingent consideration payments are included in selling, general, and administrative expenses in our condensed consolidated statements of income. For transactions involving changes in our ownership in subsidiaries without a change in our control, subsequent changes in the estimated fair value of contingent consideration payments are recognized in additional paid-in capital in our condensed consolidated balance sheet. We measure contingent consideration at the fair value on a recurring basis using significant unobservable inputs classified as Level 3 of the fair value hierarchy. We use various valuation techniques, including the Monte Carlo simulation and probability-weighted scenarios, to determine the fair value of the contingent consideration liabilities on the acquisition date and at each reporting period. Our fair value measurement inputs include expected operating performance, discount and risk-free rates, and credit spread.

**HENRY SCHEIN, INC.**  
**NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS**  
**(in millions, except share and per share data)**  
**(unaudited)**

The following table presents our assets and liabilities that are measured and recognized at fair value on a recurring basis classified under the appropriate level of the fair value hierarchy as of September 28, 2024 and December 30, 2023:

	<b>September 28, 2024</b>			
	<b>Level 1</b>	<b>Level 2</b>	<b>Level 3</b>	<b>Total</b>
<b>Assets:</b>				
Derivative contracts designated as hedges	\$ -	\$ -	\$ -	\$ -
Derivative contracts undesignated	-	2	-	2
Total return swap	-	2	-	2
<b>Total assets</b>	<b>\$ -</b>	<b>\$ 4</b>	<b>\$ -</b>	<b>\$ 4</b>
<b>Liabilities:</b>				
Derivative contracts designated as hedges	\$ -	\$ 18	\$ -	\$ 18
Derivative contracts undesignated	-	3	-	3
Contingent consideration	-	-	49	49
<b>Total liabilities</b>	<b>\$ -</b>	<b>\$ 21</b>	<b>\$ 49</b>	<b>\$ 70</b>
<b>Redeemable noncontrolling interests</b>	<b>\$ -</b>	<b>\$ -</b>	<b>\$ 832</b>	<b>\$ 832</b>
<b>December 30, 2023</b>				
	<b>Level 1</b>	<b>Level 2</b>	<b>Level 3</b>	<b>Total</b>
<b>Assets:</b>				
Derivative contracts designated as hedges	\$ -	\$ 1	\$ -	\$ 1
Derivative contracts undesignated	-	1	-	1
Total return swap	-	4	-	4
<b>Total assets</b>	<b>\$ -</b>	<b>\$ 6</b>	<b>\$ -</b>	<b>\$ 6</b>
<b>Liabilities:</b>				
Derivative contracts designated as hedges	\$ -	\$ 18	\$ -	\$ 18
Derivative contracts undesignated	-	2	-	2
<b>Total liabilities</b>	<b>\$ -</b>	<b>\$ 20</b>	<b>\$ -</b>	<b>\$ 20</b>
<b>Redeemable noncontrolling interests</b>	<b>\$ -</b>	<b>\$ -</b>	<b>\$ 864</b>	<b>\$ 864</b>

**HENRY SCHEIN, INC.**  
**NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS**  
**(in millions, except share and per share data)**  
**(unaudited)**

**Note 8 – Debt***Bank Credit Lines*

Bank credit lines consisted of the following:

	September 28, 2024	December 30, 2023
Revolving credit agreement	\$ 50	\$ 200
Other short-term bank credit lines	588	64
Total	<u>\$ 638</u>	<u>\$ 264</u>

*Revolving Credit Agreement*

On August 20, 2021, we entered into a \$1.0 billion revolving credit agreement (the “Revolving Credit Agreement”) which was subsequently amended and restated on July 11, 2023 to extend the maturity date to July 11, 2028 and update the interest rate provisions to reflect the current market approach for a multicurrency facility. The interest rate on this revolving credit facility is based on Term Secured Overnight Financing Rate (“Term SOFR”) plus a spread based on our leverage ratio at the end of each financial reporting quarter. As of September 28, 2024 the interest rate on this revolving credit facility was 4.96% plus 1.18% for a combined rate of 6.14%. As of December 30, 2023 the interest rate on this revolving credit facility was 5.36% plus 1.00% for a combined rate of 6.36%.

The Revolving Credit Agreement requires, among other things, that we maintain certain maximum leverage ratios. Additionally, the Revolving Credit Agreement contains customary representations, warranties and affirmative covenants as well as customary negative covenants, subject to negotiated exceptions, on liens, indebtedness, significant corporate changes (including mergers), dispositions and certain restrictive agreements. As of September 28, 2024 and December 30, 2023, we had \$50 million and \$200 million in borrowings, respectively under this revolving credit facility. During the nine months ended September 28, 2024, the average outstanding balance under the Revolving Credit Agreement was approximately \$64 million. As of September 28, 2024 and December 30, 2023, there were \$11 million and \$10 million of letters of credit, respectively, provided to third parties under the Revolving Credit Agreement.

*Other Short-Term Bank Credit Lines*

As of September 28, 2024 and December 30, 2023, we had various other short-term bank credit lines available, in various currencies, with a maximum borrowing capacity of \$689 million and \$368 million, respectively. As of September 28, 2024 and December 30, 2023, \$588 million and \$64 million, respectively, were outstanding. During the nine months ended September 28, 2024, the average outstanding balances under our various other short-term bank credit lines was approximately \$426 million. As of September 28, 2024 and December 30, 2023, borrowings under other short-term bank credit lines had weighted average interest rates of 5.94% and 6.02%, respectively.

**HENRY SCHEIN, INC.**  
**NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS**  
**(in millions, except share and per share data)**  
**(unaudited)**

*Long-term debt*

Long-term debt consisted of the following:

	September 28, 2024	December 30, 2023
Private placement facilities	\$ 1,024	\$ 1,074
Term loan	722	741
U.S. trade accounts receivable securitization	210	210
Various collateralized and uncollateralized loans payable with interest, in varying installments through 2031 at interest rates from 0.00% to 9.42% at September 28, 2024 and from 0.00% to 9.42% at December 30, 2023	52	54
Finance lease obligations	7	8
Total	2,015	2,087
Less current maturities	(109)	(150)
Total long-term debt	<u>\$ 1,906</u>	<u>\$ 1,937</u>

*Private Placement Facilities*

Our private placement facilities provided by four insurance companies, have a total facility amount of \$1.5 billion, and are available on an uncommitted basis at fixed rate economic terms to be agreed upon at the time of issuance, from time to time through October 20, 2026. The facilities allow us to issue senior promissory notes to the lenders at a fixed rate based on an agreed upon spread over applicable treasury notes at the time of issuance. The term of each possible issuance will be selected by us and can range from five to 15 years (with an average life no longer than 12 years). The proceeds of any issuances under the facilities will be used for general corporate purposes, including working capital and capital expenditures, to refinance existing indebtedness, and/or to fund potential acquisitions. The agreements provide, among other things, that we maintain certain maximum leverage ratios, and contain restrictions relating to subsidiary indebtedness, liens, affiliate transactions, disposal of assets and certain changes in ownership. These facilities contain make-whole provisions in the event that we pay off the facilities prior to the applicable due dates.

The components of our private placement facility borrowings, which have a weighted average interest rate of 3.66%, as of September 28, 2024 are presented in the following table:

Date of Borrowing	Amount of Borrowing Outstanding	Borrowing Rate	Due Date
December 24, 2012	\$ 50	3.00%	December 24, 2024
June 16, 2017	100	3.42	June 16, 2027
September 15, 2017	100	3.52	September 15, 2029
January 2, 2018	100	3.32	January 2, 2028
September 2, 2020	100	2.35	September 2, 2030
June 2, 2021	100	2.48	June 2, 2031
June 2, 2021	100	2.58	June 2, 2033
May 4, 2023	75	4.79	May 4, 2028
May 4, 2023	75	4.84	May 4, 2030
May 4, 2023	75	4.96	May 4, 2033
May 4, 2023	150	4.94	May 4, 2033
Less: Deferred debt issuance costs	(1)		
Total	<u>\$ 1,024</u>		



**HENRY SCHEIN, INC.**  
**NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS**  
**(in millions, except share and per share data)**  
**(unaudited)**

*Term Loan*

On July 11, 2023, we entered into a three-year \$750 million term loan credit agreement (the “Term Credit Agreement”). The interest rate on this term loan is based on the Term SOFR plus a spread based on our leverage ratio at the end of each financial reporting quarter. This term loan matures on July 11, 2026. We are required to make quarterly payments of \$9 million from September 2024 through June 2026, with the remaining balance due in July 2026. Previously, we had been required to make quarterly payments of \$5 million from September 2023 through June 2024. As of September 28, 2024, the borrowings outstanding under this term loan were \$722 million. At September 28, 2024, the interest rate under the Term Credit Agreement was 5.10% plus 1.60% for a combined rate of 6.70%. As of December 30, 2023, the borrowings outstanding under this term loan were \$741 million. At December 30, 2023, the interest rate under the Term Credit Agreement was 5.36% plus 1.35% for a combined rate of 6.71%. However, we have a hedge in place that ultimately creates an effective fixed rate of 6.04% and 5.79% at September 28, 2024 and December 30, 2023, respectively. The Term Credit Agreement requires, among other things, that we maintain certain maximum leverage ratios. Additionally, the Term Credit Agreement contains customary representations, warranties and affirmative covenants as well as customary negative covenants, subject to negotiated exceptions, on liens, indebtedness, significant corporate changes (including mergers), dispositions and certain restrictive agreements.

*U.S. Trade Accounts Receivable Securitization*

We have a facility agreement based on our U.S. trade accounts receivable that is structured as an asset-backed securitization program with pricing committed for up to three years. This facility agreement has a purchase limit of \$450 million with two banks as agents, and expires on December 15, 2025.

As of September 28, 2024 and December 30, 2023, the borrowings outstanding under this securitization facility were \$210 million and \$210 million, respectively. At September 28, 2024, the interest rate on borrowings under this facility was based on the asset-backed commercial paper rate of 5.28% plus 0.75%, for a combined rate of 6.03%. At December 30, 2023, the interest rate on borrowings under this facility was based on the asset-backed commercial paper rate of 5.67% plus 0.75%, for a combined rate of 6.42%.

If our accounts receivable collection pattern changes due to customers either paying late or not making payments, our ability to borrow under this facility may be reduced.

We are required to pay a commitment fee of 30 to 35 basis points depending upon program utilization.

**HENRY SCHEIN, INC.**  
**NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS**  
**(in millions, except share and per share data)**  
**(unaudited)**

**Note 9 – Income Taxes**

For the nine months ended September 28, 2024 our effective tax rate was 25.1%, compared to 22.5% for the prior year period. The difference between our effective tax rate and the federal statutory tax rate primarily relates to state and foreign income taxes and interest expense.

The Organization of Economic Co-Operation and Development (OECD) issued technical and administrative guidance on Pillar Two rules in December 2021, which provides for a global minimum tax rate on the earnings of large multinational businesses on a country-by-country basis. Effective January 1, 2024, the minimum global tax rate is 15% for various jurisdictions pursuant to the Pillar Two rules. As of September 28, 2024, the impact of the Pillar Two rules to our financial statements was immaterial. As we operate in jurisdictions which have adopted Pillar Two, we are continuing to analyze the implications to effectively manage the impact for 2024 and beyond. Future tax reform resulting from these developments may result in changes to long-standing tax principles, which may adversely impact our effective tax rate going forward or result in higher cash tax liabilities.

The total amount of unrecognized tax benefits, which are included in “other liabilities” within our condensed consolidated balance sheets, as of September 28, 2024 and December 30, 2023, was \$107 million and \$115 million, respectively, of which \$99 million and \$107 million, respectively, would affect the effective tax rate if recognized. It is possible that the amount of unrecognized tax benefits will change in the next 12 months, which may result in a material impact on our condensed consolidated statements of income.

All tax returns audited by the IRS are officially closed through 2020. The tax years subject to examination by the IRS include years 2021 and forward. In addition, limited positions reported in the 2017 tax year are subject to IRS examination.

The amount of tax interest expense included as a component of the provision for taxes was \$1 million and \$3 million for the nine months ended September 28, 2024 and September 30, 2023, respectively. The total amount of accrued interest is included in “other liabilities,” and was \$18 million as of September 28, 2024 and \$16 million as of December 30, 2023. The amount of penalties accrued for during the periods presented was not material to our condensed consolidated financial statements.

**HENRY SCHEIN, INC.**  
**NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS**  
**(in millions, except share and per share data)**  
**(unaudited)**

**Note 10 – Plans of Restructuring**

On August 1, 2022, we committed to a restructuring plan (the “2022 Plan”) focused on funding the priorities of the BOLD+1 strategic plan, streamlining operations and other initiatives to increase efficiency. The 2022 Plan has been completed as of July 31, 2024. During the three months ended September 28, 2024 and September 30, 2023, in connection with our 2022 Plan, we recorded restructuring costs of \$12 million and \$11 million, respectively. During the nine months ended September 28, 2024 and September 30, 2023, in connection with our 2022 Plan, we recorded restructuring costs of \$37 million and \$59 million, respectively. The restructuring costs for these periods primarily related to severance and employee-related costs, accelerated amortization of right-of-use lease assets and fixed assets, and other exit costs. We expect to record immaterial charges associated with the 2022 Plan during the remainder of 2024.

On August 6, 2024, we committed to a new restructuring plan (the “2024 Plan”) to integrate recent acquisitions, right-size operations and further increase efficiencies. During the three and nine months ended September 28, 2024, we recorded restructuring charges associated with the 2024 Plan of \$36 million which primarily related to severance and employee-related costs, accelerated amortization of right-of-use lease assets and fixed assets, and other lease exit costs. We expect to record restructuring charges associated with the 2024 Plan during the fourth quarter of 2024 and in 2025, however an estimate of the amount of these charges has not yet been determined.

Restructuring costs recorded for the three and nine months ended September 28, 2024 and September 30, 2023, in connection with the 2022 Plan and 2024 Plan consisted of the following:

	Three Months Ended September 28, 2024			Nine Months Ended September 28, 2024		
	Health Care Distribution	Technology and Value- Added Services	Total	Health Care Distribution	Technology and Value- Added Services	Total
<b><i>2024 Plan</i></b>						
Severance and employee-related costs	\$ 26	\$ 5	\$ 31	\$ 26	\$ 5	\$ 31
Accelerated depreciation and amortization	2	2	4	2	2	4
Exit and other related costs	1	-	1	1	-	1
Restructuring costs-2024 Plan	\$ 29	\$ 7	\$ 36	\$ 29	\$ 7	\$ 36
<b><i>2022 Plan</i></b>						
Severance and employee-related costs	\$ 7	\$ 1	\$ 8	\$ 21	\$ 3	\$ 24
Accelerated depreciation and amortization	1	-	1	7	-	7
Exit and other related costs	1	2	3	4	2	6
Restructuring costs-2022 Plan	\$ 9	\$ 3	\$ 12	\$ 32	\$ 5	\$ 37
Total restructuring costs	\$ 38	\$ 10	\$ 48	\$ 61	\$ 12	\$ 73

**HENRY SCHEIN, INC.**  
**NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS**  
**(in millions, except share and per share data)**  
**(unaudited)**

	Three Months Ended September 30, 2023			Nine Months Ended September 30, 2023		
	Health Care Distribution	Technology and Value- Added Services	Total	Health Care Distribution	Technology and Value- Added Services	Total
<b><i>2022 Plan</i></b>						
Severance and employee-related costs	\$ 6	\$ -	\$ 6	\$ 36	\$ 4	\$ 40
Accelerated depreciation and amortization	3	1	4	12	2	14
Exit and other related costs	1	-	1	3	1	4
Loss on disposal of a business	-	-	-	1	-	1
Total restructuring costs	<u>\$ 10</u>	<u>\$ 1</u>	<u>\$ 11</u>	<u>\$ 52</u>	<u>\$ 7</u>	<u>\$ 59</u>

The following table summarizes, by plan year, the activity related to the liabilities associated with our restructuring initiatives under the 2022 Plan and the 2024 Plan for the nine months ended September 28, 2024. The remaining accrued balance of restructuring costs as of September 28, 2024, which primarily relates to severance and employee-related costs, is included in accrued expenses: other within our condensed consolidated balance sheets. Liabilities related to exited leased facilities are recorded within our current and non-current operating lease liabilities within our condensed consolidated balance sheets.

	2022 Plan	2024 Plan	Total
Balance, December 30, 2023	\$ 23	\$ -	\$ 23
Restructuring costs	37	36	73
Non-cash accelerated depreciation and amortization	(7)	(4)	(11)
Cash payments and other adjustments	(35)	(7)	(42)
Balance, September 28, 2024	<u>\$ 18</u>	<u>\$ 25</u>	<u>\$ 43</u>

**HENRY SCHEIN, INC.**  
**NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS**  
**(in millions, except share and per share data)**  
**(unaudited)**

**Note 11 – Legal Proceedings**

Henry Schein, Inc. has been named as a defendant in multiple opioid related lawsuits (currently less than one-hundred and seventy-five (175); one or more of Henry Schein, Inc.'s subsidiaries is also named as a defendant in a number of those cases). Generally, the lawsuits allege that the manufacturers of prescription opioid drugs engaged in a false advertising campaign to expand the market for such drugs and their own market share and that the entities in the supply chain (including Henry Schein, Inc. and its subsidiaries) reaped financial rewards by refusing or otherwise failing to monitor appropriately and restrict the improper distribution of those drugs. These actions consist of some that have been consolidated within the MultiDistrict Litigation (“MDL”) proceeding In Re National Prescription Opiate Litigation (MDL No. 2804; Case No. 17-md-2804) and are currently stayed, and others which remain pending in state courts and are proceeding independently and outside of the MDL. At this time, the following case is set for trial: the action filed by Florida Health Sciences Center, Inc. (and 25 other hospitals located throughout the State of Florida) in Florida state court, which is currently scheduled for a jury trial in September 2025. Of Henry Schein’s 2023 net sales of approximately \$12.3 billion, sales of opioids represented less than four-tenths of 1 percent. Opioids represent a negligible part of our business. We intend to defend ourselves vigorously against these actions.

In August 2022, Henry Schein received a Grand Jury Subpoena from the United States Attorney’s Office for the Western District of Virginia, seeking documents in connection with an investigation of possible violations of the Federal Food, Drug & Cosmetic Act by Butler Animal Health Supply, LLC (“Butler”), a former subsidiary of Henry Schein. The investigation relates to the sale of veterinary prescription drugs to certain customers. In October 2022, Henry Schein received a second Grand Jury Subpoena from the United States Attorney’s Office for the Western District of Virginia. The October 2022 Subpoena seeks documents relating to payments Henry Schein received from Butler or Covetrus, Inc. (“Covetrus”). Butler was spun off into a separate company and became a subsidiary of Covetrus in 2019 and is no longer owned by Henry Schein. We are cooperating with the investigation.

On January 18, 2024, a putative class action was filed against the Company in the U.S. District Court for the Eastern District of New York (“EDNY”), Case No. 24-cv-387 (the “Cruz-Bermudez Action”), based on the October 2023 cyber incident described in [Note 3 – Cyber Incident](#). On January 26, 2024, a second putative class action was filed against the Company based on the cyber incident, also in the EDNY, Case No. 24-cv-550 (the “Depperschmidt Action”). On February 12, 2024, the Depperschmidt Action was voluntarily dismissed without prejudice. On February 16, 2024, an amended complaint was filed in the Cruz-Bermudez Action with additional plaintiffs’ counsel from the Depperschmidt Action and an additional new plaintiff.

Plaintiffs in the Cruz-Bermudez Action seek to represent a class of all individuals whose personally identifying information and personal health information was compromised by the incident. Plaintiffs generally claim to have been harmed by alleged actions and/or omissions by the Company in connection with the incident and that the Company made deceptive public statements regarding privacy and data protection. Plaintiffs assert a variety of claims seeking monetary damages, injunctive relief, costs and attorneys’ fees, and other related relief. On March 22, 2024, plaintiffs voluntarily withdrew two of their five causes of action. On April 8, 2024, the court denied the Company’s motion to dismiss the remaining claims. The case remains pending.

On June 6, 2024, plaintiffs and the Company informed the court that they had agreed to a term sheet for a class action settlement of the Cruz-Bermudez Action. Plaintiffs and the Company entered into a class action settlement agreement on September 13, 2024, and the court preliminarily approved the settlement on September 16, 2024. Under the terms of the proposed settlement, all claims in the Cruz-Bermudez Action will be dismissed, the Cruz-Bermudez Action will be terminated, the Company will receive a release of claims from the class, and the Company will pay \$2.9 million into a fund for class members. The proposed settlement is subject to the court’s final approval. The court has scheduled a fairness hearing on the proposed settlement for February 14, 2025.

**HENRY SCHEIN, INC.**  
**NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS**  
**(in millions, except share and per share data)**  
**(unaudited)**

Henry Schein, Inc. and its subsidiary, North American Rescue, LLC (“NAR”), were named as defendants in a qui tam lawsuit brought under the federal False Claims Act (“FCA”), in an action entitled *Russ and Murphy ex rel. United States v. North American Rescue, LLC et al.*; Case No. 21-cv-04238, filed in the United States District Court for the Eastern District of Pennsylvania. The case was filed under seal in 2021 by two relators (Corey Russ and Chris Murphy) who worked for one of NAR’s competitors. Relators also name C-A-T Resources, LLC (“CAT-R”) as a defendant. CAT-R manufactures one of the products at issue in the case (the combat application tourniquet, or “CAT”). After the Department of Justice declined to intervene, the case was unsealed, and Relators filed their first amended complaint in November 2023. In response to motions to dismiss filed by Henry Schein, NAR and CAT-R, Relators requested and obtained leave to file their Second Amended Complaint on April 24, 2024. On July 26, 2024, the court ruled on motions to dismiss filed by Henry Schein, NAR and CAT-R. The court dismissed the claims against Henry Schein (without prejudice). The motions to dismiss filed by NAR and CAT-R were denied. Relators’ FCA claims are based on allegations that NAR made false representations and certifications in connection with, and sold and submitted false claims for payment to the federal government for, various medical products that Relators contend violated certain “Buy American” laws (e.g., the Berry Amendment and Trade Agreements Act of 1979) and/or were not properly sterilized as noted on the products’ packaging, and thus misbranded. These products include the CAT, syringes, compressed gauze, tracheostomy kits, hypothermia blankets, eye, ear, nose and throat kits, and trauma dressing. Relators sought three times the amount of damages to be proved at trial, statutory civil penalties, reasonable expenses, attorneys’ fees and costs, and prejudgment interest. Pursuant to a settlement for an immaterial amount, the court has dismissed the case with prejudice.

From time to time, we may become a party to other legal proceedings, including, without limitation, product liability claims, employment matters, commercial disputes, governmental inquiries and investigations (which may in some cases involve our entering into settlement arrangements or consent decrees), and other matters arising out of the ordinary course of our business. While the results of any legal proceeding cannot be predicted with certainty, in our opinion none of these other pending matters are currently anticipated to have a material adverse effect on our consolidated financial position, liquidity or results of operations.

As of September 28, 2024, we had accrued our best estimate of potential losses relating to claims that were probable to result in liability and for which we were able to reasonably estimate a loss. This accrued amount, as well as related expenses, was not material to our financial position, results of operations or cash flows. Our method for determining estimated losses considers currently available facts, presently enacted laws and regulations and other factors, including probable recoveries from third parties.

**HENRY SCHEIN, INC.**  
**NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS**  
**(in millions, except share and per share data)**  
**(unaudited)**

**Note 12 – Stock-Based Compensation**

Stock-based awards are provided to certain employees under our 2024 Stock Incentive Plan (formerly known as our 2020 Stock Incentive Plan) and to non-employee directors under our 2023 Non-Employee Director Stock Incentive Plan (together, the “Plans”). The Plans are administered by the Compensation Committee of the Board of Directors (the “Compensation Committee”). Historically, equity-based awards to our employees have been granted solely in the form of time-based and performance-based restricted stock units (“RSUs”) with the exception of our 2021 plan year in which non-qualified stock options were issued in place of performance-based RSUs and in 2022, when we granted time-based and performance-based RSUs, as well as non-qualified stock options. Starting with our 2023 plan year, we returned to granting our employees equity-based awards solely in the form of time-based and performance-based RSUs. Our non-employee directors receive equity-based awards solely in the form of time-based RSUs.

RSUs are stock-based awards granted to recipients with specified vesting provisions. In the case of RSUs, common stock is delivered on or following satisfaction of vesting conditions. We issue RSUs to employees that primarily vest (i) solely based on the recipient’s continued service over time, primarily with four-year cliff vesting and/or (ii) based on achieving specified performance measurements and the recipient’s continued service over time, primarily with three-year cliff vesting. RSUs granted to our non-employee directors primarily include 12-month cliff vesting. For these RSUs, we recognize the cost as compensation expense on a straight-line basis.

For all RSUs, we estimate the fair value based on our closing stock price on the grant date. With respect to performance-based RSUs, the number of shares that ultimately vest and are received by the recipient is based upon our performance as measured against specified targets over a specified period, as determined by the Compensation Committee. Although there is no guarantee that performance targets will be achieved, we estimate the fair value of performance-based RSUs based on our closing stock price at time of grant.

Each of the Plans provide for certain adjustments to the performance measurement in connection with awards under the Plans. With respect to the performance-based RSUs granted under our 2024 Stock Incentive Plan, such performance measurement adjustments relate to significant events, including, without limitation, acquisitions, divestitures, new business ventures, certain capital transactions (including share repurchases), differences in budgeted average outstanding shares (other than those resulting from capital transactions referred to above), restructuring costs, if any, amortization expense recorded for acquisition-related intangible assets (solely with respect to performance-based RSUs granted in the 2023 and 2024 plan years), certain litigation settlements or payments, if any, changes in accounting principles or in applicable laws or regulations, changes in income tax rates in certain markets, foreign exchange fluctuations, the financial impact either positive or negative, of the difference in projected earnings generated by COVID-19 test kits (solely with respect to performance-based RSUs granted in the 2022 and 2023 plan years) and impairment charges (solely with respect to performance-based RSUs granted in the 2023 and 2024 plan years), and unforeseen events or circumstances affecting us.

**HENRY SCHEIN, INC.**  
**NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS**  
**(in millions, except share and per share data)**  
**(unaudited)**

Over the performance period, the number of RSUs that will ultimately vest and be issued and the related compensation expense is adjusted upward or downward based upon our estimation of achieving such performance targets. The ultimate number of shares delivered to recipients and the related compensation cost recognized as an expense is based on our actual performance against the pre-determined performance metrics (in each case as adjusted).

Stock options are awards that allow the recipient to purchase shares of our common stock after vesting at a fixed price set at the time of grant. Stock options were granted at an exercise price equal to our closing stock price on the date of grant. Stock options issued in 2021 and 2022 vest one-third per year based on the recipient's continued service, subject to the terms and conditions of the 2020 Stock Incentive Plan, are fully vested three years from the grant date and have a contractual term of ten years from the grant date, subject to earlier termination of term and term acceleration upon certain events. Compensation expense for stock options is recognized using a graded vesting method. We estimate grant date fair value of stock options using the Black-Scholes valuation model. During the nine months ended September 28, 2024, we did not grant any stock options.

Our condensed consolidated statements of income reflect pre-tax share-based compensation expense of \$10 million, and \$30 million for the three and nine months ended September 28, 2024, respectively. For the three and nine months ended September 30, 2023, we recorded pre-tax share-based compensation expense of \$14 million, and \$38 million.

Total unrecognized compensation cost related to unvested awards as of September 28, 2024 was \$83 million, which is expected to be recognized over a weighted-average period of approximately 2.6 years.

Our condensed consolidated statements of cash flows present our stock-based compensation expense as a reconciling adjustment between net income and net cash provided by operating activities for all periods presented. There were no cash benefits associated with tax deductions in excess of recognized compensation for the nine months ended September 28, 2024 and September 30, 2023.

The following table summarizes the stock option activity for the nine months ended September 28, 2024:

	<b>Stock Options</b>			
	<b>Shares</b>	<b>Weighted Average Exercise Price</b>	<b>Weighted Average Remaining Contractual Life (in years)</b>	<b>Aggregate Intrinsic Value</b>
Outstanding at beginning of period	1,078,459	\$ 71.46		
Granted	-	-		
Exercised	(48,842)	62.71		
Forfeited	(10,980)	85.31		
Outstanding at end of period	<u>1,018,637</u>	\$ 71.73	6.8	\$ 6
Options exercisable at end of period	<u>887,589</u>	\$ 69.70		
	<b>Number of Options</b>	<b>Weighted Average Exercise Price</b>	<b>Weighted Average Remaining Contractual Life (in years)</b>	<b>Aggregate Intrinsic Value</b>
Expected to vest	131,048	\$ 85.51	7.5	\$ -



**HENRY SCHEIN, INC.**  
**NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS**  
**(in millions, except share and per share data)**  
**(unaudited)**

The following tables summarize the activity of our unvested RSUs for the nine months ended September 28, 2024:

	Time-Based Restricted Stock Units			Performance-Based Restricted Stock Units		
	Shares/Units	Weighted	Intrinsic	Shares/Units	Weighted	Intrinsic
		Average			Average	
	Grant Date Fair	Value	Grant Date Fair	Value	Value	
	Value Per Share	Per Share	Value Per Share	Per Share	Per Share	
Outstanding at beginning of period	1,655,393	\$ 70.34		208,742	\$ 78.02	
Granted	465,339	75.83		329,118	76.70	
Vested	(329,115)	63.00		(8,262)	66.53	
Forfeited	(87,304)	77.19		(55,976)	79.69	
Outstanding at end of period	<u>1,704,313</u>	<u>\$ 72.92</u>	<u>\$ 73.22</u>	<u>473,622</u>	<u>\$ 75.91</u>	<u>\$ 73.22</u>

**Note 13 – Redeemable Noncontrolling Interests**

Some minority stockholders in certain of our subsidiaries have the right, at certain times, to require us to acquire their ownership interest in those entities at fair value. Accounting Standards Codification Topic 480-10 is applicable for noncontrolling interests where we are or may be required to purchase all or a portion of the outstanding interest in a consolidated subsidiary from the noncontrolling interest holder under the terms of a put option contained in contractual agreements. The components of the change in the redeemable noncontrolling interests for the nine months ended September 28, 2024 and the year ended December 30, 2023 are presented in the following table:

	September 28, 2024	December 30, 2023
Balance, beginning of period	\$ 864	\$ 576
Decrease in redeemable noncontrolling interests due to acquisitions of noncontrolling interests in subsidiaries	(257)	(19)
Increase in redeemable noncontrolling interests due to business acquisitions	172	326
Net income attributable to redeemable noncontrolling interests	-	6
Distributions declared, net of capital contributions	(30)	(19)
Effect of foreign currency translation gain (loss) attributable to redeemable noncontrolling interests	(4)	5
Change in fair value of redeemable securities	87	(11)
Balance, end of period	<u>\$ 832</u>	<u>\$ 864</u>

**HENRY SCHEIN, INC.**  
**NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS**  
**(in millions, except share and per share data)**  
**(unaudited)**

**Note 14 – Comprehensive Income**

Comprehensive income includes certain gains and losses that, under U.S. GAAP, are excluded from net income and are recorded directly to stockholders' equity.

The following table summarizes our Accumulated other comprehensive loss, net of applicable taxes as of:

	<b>September 28, 2024</b>	<b>December 30, 2023</b>
<b>Attributable to redeemable noncontrolling interests:</b>		
Foreign currency translation adjustment	\$ (36)	\$ (32)
<b>Attributable to noncontrolling interests:</b>		
Foreign currency translation adjustment	\$ -	\$ (1)
<b>Attributable to Henry Schein, Inc.:</b>		
Foreign currency translation adjustment	\$ (243)	\$ (188)
Unrealized gain loss from hedging activities	(16)	(13)
Pension adjustment loss	(5)	(5)
Accumulated other comprehensive loss	<u>\$ (264)</u>	<u>\$ (206)</u>
<b>Total Accumulated other comprehensive loss</b>	<u><u>\$ (300)</u></u>	<u><u>\$ (239)</u></u>

The following table summarizes the components of comprehensive income, net of applicable taxes as follows:

	<b>Three Months Ended</b>		<b>Nine Months Ended</b>	
	<b>September 28, 2024</b>	<b>September 30, 2023</b>	<b>September 28, 2024</b>	<b>September 30, 2023</b>
Net income	\$ 99	\$ 143	\$ 302	\$ 419
Foreign currency translation gain (loss)	58	(45)	(58)	(17)
Tax effect	-	-	-	-
Foreign currency translation gain (loss)	<u>58</u>	<u>(45)</u>	<u>(58)</u>	<u>(17)</u>
Unrealized gain (loss) from hedging activities	(25)	9	(4)	3
Tax effect	7	(3)	1	(1)
Unrealized gain (loss) from hedging activities	<u>(18)</u>	<u>6</u>	<u>(3)</u>	<u>2</u>
<b>Comprehensive income</b>	<u><u>\$ 139</u></u>	<u><u>\$ 104</u></u>	<u><u>\$ 241</u></u>	<u><u>\$ 404</u></u>

Our financial statements are denominated in U.S. Dollars. Fluctuations in the value of foreign currencies as compared to the U.S. Dollar may have a significant impact on our comprehensive income. The foreign currency translation gain (loss) during the nine months ended September 28, 2024 and nine months ended September 30, 2023 was primarily due to changes in foreign currency exchange rates of the Brazilian Real, British Pound, Euro, Swiss Franc, Canadian Dollar, and Australian Dollar.

The hedging gain (loss) during the three and nine months ended September 28, 2024, and September 30, 2023 was attributable to a net investment hedge.

The following table summarizes our total comprehensive income, net of applicable taxes as follows:

**HENRY SCHEIN, INC.**  
**NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS**  
**(in millions, except share and per share data)**  
**(unaudited)**

	Three Months Ended		Nine Months Ended	
	September 28, 2024	September 30, 2023	September 28, 2024	September 30, 2023
Comprehensive income attributable to Henry Schein, Inc.	\$ 127	\$ 100	\$ 238	\$ 384
Comprehensive income attributable to noncontrolling interests	-	4	7	10
Comprehensive income (loss) attributable to Redeemable noncontrolling interests	12	-	(4)	10
Comprehensive income	<u>\$ 139</u>	<u>\$ 104</u>	<u>\$ 241</u>	<u>\$ 404</u>

**Note 15 – Earnings Per Share**

Basic earnings per share is computed by dividing net income attributable to Henry Schein, Inc. by the weighted-average number of common shares outstanding for the period. Our diluted earnings per share is computed similarly to basic earnings per share, except that it reflects the effect of common shares issuable for unvested RSUs and upon exercise of stock options using the treasury stock method in periods in which they have a dilutive effect.

A reconciliation of shares used in calculating earnings per basic and diluted share follows:

	Three Months Ended		Nine Months Ended	
	September 28, 2024	September 30, 2023	September 28, 2024	September 30, 2023
Basic	126,124,715	130,388,353	127,550,045	130,888,717
Effect of dilutive securities:				
Stock options and restricted stock units	930,219	1,053,782	948,449	1,260,455
Diluted	<u>127,054,934</u>	<u>131,442,135</u>	<u>128,498,494</u>	<u>132,149,172</u>

The number of antidilutive securities that were excluded from the calculation of diluted weighted average common shares outstanding are as follows:

	Three Months Ended		Nine Months Ended	
	September 28, 2024	September 30, 2023	September 28, 2024	September 30, 2023
Stock options	412,574	424,005	416,065	426,237
Restricted stock units	17,627	7,362	16,339	15,072
Total anti-dilutive securities excluded from earnings per share computation	<u>430,201</u>	<u>431,367</u>	<u>432,404</u>	<u>441,309</u>

**Note 16 – Supplemental Cash Flow Information**

Cash paid for interest and income taxes was:

	Nine Months Ended	
	September 28, 2024	September 30, 2023
Interest	\$ 92	\$ 52
Income taxes	127	178

For the nine months ended September 28, 2024 and September 30, 2023, we had \$(4) million and \$3 million of non-cash net unrealized gains (losses) related to hedging activities, respectively.

**HENRY SCHEIN, INC.**  
**NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS**  
**(in millions, except share and per share data)**  
**(unaudited)**

**Note 17 – Related Party Transactions**

In connection with the formation of Henry Schein One, LLC, our joint venture with Internet Brands, which was formed on July 1, 2018, we entered into a ten-year royalty agreement with Internet Brands whereby we will pay Internet Brands approximately \$31 million annually for the use of their intellectual property. During the three and nine months ended September 28, 2024, we recorded \$8 million and \$23 million, respectively, within selling, general and administrative in our condensed consolidated statements of income, in connection with costs related to this royalty agreement. During the three and nine months ended September 30, 2023 we recorded \$8 million and \$23 million, respectively, within selling, general and administrative in our condensed consolidated statements of income, in connection with costs related to this royalty agreement. As of September 28, 2024 and December 30, 2023, Henry Schein One, LLC had a net payable balance to Internet Brands of \$10 million and \$1 million, respectively, comprised of amounts related to results of operations and the royalty agreement. The components of this payable are recorded within accrued expenses: other within our condensed consolidated balance sheets.

We have interests in entities that we account for under the equity accounting method. In our normal course of business, during the three and nine months ended September 28, 2024, we recorded net sales of \$14 million and \$38 million respectively, to such entities. During the three and nine months ended September 30, 2023, we recorded net sales of \$11 million and \$34 million respectively, to such entities. During the three and nine months ended September 28, 2024, we purchased \$2 million and \$8 million respectively, from such entities. During the three and nine months ended September 30, 2023, we purchased \$1 million and \$7 million respectively, from such entities. At September 28, 2024 and December 30, 2023, we had an aggregate \$32 million and \$32 million, respectively, due from our equity affiliates, and \$8 million and \$5 million, respectively, due to our equity affiliates.

Certain of our facilities related to our acquisitions are leased from employees and minority shareholders. These leases are classified as operating leases and have a remaining lease term ranging from six months to 13 years. As of September 28, 2024, current and non-current liabilities associated with related party operating leases were \$6 million and \$22 million, respectively. At September 28, 2024, related party leases represented 7.4% and 8.3% of the total current and non-current operating lease liabilities, respectively. At December 30, 2023, current and non-current liabilities associated with related party operating leases were \$5 million and \$23 million, respectively. At December 30, 2023, related party leases represented 6.3% and 7.4% of the total current and non-current operating lease liabilities, respectively.

## ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

### Cautionary Note Regarding Forward-Looking Statements

In accordance with the "Safe Harbor" provisions of the Private Securities Litigation Reform Act of 1995, we provide the following cautionary remarks regarding important factors that, among others, could cause future results to differ materially from the forward-looking statements, expectations and assumptions expressed or implied herein. All forward-looking statements made by us are subject to risks and uncertainties and are not guarantees of future performance. These forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, performance and achievements or industry results to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. These statements are generally identified by the use of such terms as "may," "could," "expect," "intend," "believe," "plan," "estimate," "forecast," "project," "anticipate," "to be," "to make" or other comparable terms. Factors that could cause or contribute to such differences include, but are not limited to, those discussed in the documents we file with the Securities and Exchange Commission (SEC), including our Annual Report on Form 10-K.

Risk factors and uncertainties that could cause actual results to differ materially from current and historical results include, but are not limited to: our dependence on third parties for the manufacture and supply of our products; our ability to develop or acquire and maintain and protect new products (particularly technology products) and technologies that achieve market acceptance with acceptable margins; transitional challenges associated with acquisitions, dispositions and joint ventures, including the failure to achieve anticipated synergies/benefits, as well as significant demands on our operations, information systems, legal, regulatory, compliance, financial and human resources functions in connection with acquisitions, dispositions and joint ventures; certain provisions in our governing documents that may discourage third-party acquisitions of us; adverse changes in supplier rebates or other purchasing incentives; risks related to the sale of corporate brand products; security risks associated with our information systems and technology products and services, such as cyberattacks or other privacy or data security breaches (including the October 2023 incident); effects of a highly competitive (including, without limitation, competition from third-party online commerce sites) and consolidating market; changes in the health care industry; risks from expansion of customer purchasing power and multi-tiered costing structures; increases in shipping costs for our products or other service issues with our third-party shippers; general global and domestic macro-economic and political conditions, including inflation, deflation, recession, ongoing wars, fluctuations in energy pricing and the value of the U.S. dollar as compared to foreign currencies, and changes to other economic indicators, international trade agreements, potential trade barriers and terrorism; geopolitical wars; failure to comply with existing and future regulatory requirements; risks associated with the EU Medical Device Regulation; failure to comply with laws and regulations relating to health care fraud or other laws and regulations; failure to comply with laws and regulations relating to the collection, storage and processing of sensitive personal information or standards in electronic health records or transmissions; changes in tax legislation; risks related to product liability, intellectual property and other claims; risks associated with customs policies or legislative import restrictions; risks associated with disease outbreaks, epidemics, pandemics (such as the COVID-19 pandemic), or similar wide-spread public health concerns and other natural or man-made disasters; risks associated with our global operations; litigation risks; new or unanticipated litigation developments and the status of litigation matters; our dependence on our senior management, employee hiring and retention, and our relationships with customers, suppliers and manufacturers; and disruptions in financial markets. The order in which these factors appear should not be construed to indicate their relative importance or priority.

We caution that these factors may not be exhaustive and that many of these factors are beyond our ability to control or predict. Accordingly, any forward-looking statements contained herein should not be relied upon as a prediction of actual results. We undertake no duty and have no obligation to update forward-looking statements except as required by law.

## **Where You Can Find Important Information**

We may disclose important information through one or more of the following channels: SEC filings, public conference calls and webcasts, press releases, the investor relations page of our website ([www.henryschein.com](http://www.henryschein.com)) and the social media channels identified on the About Media Center page of our website.

## **Recent Developments**

While the U.S. economy has experienced inflationary pressures and strengthening of the U.S. dollar, their impacts have not been material to our results of operations. Though inflation impacts both our revenues and costs, the depth and breadth of our product portfolio often allows us to offer lower-cost national brand solutions or corporate brand alternatives to our more price-sensitive customers who are unwilling to absorb price increases, thus positioning us to protect our gross profit.

### *Cyber Incident*

In October 2023 Henry Schein experienced a cyber incident that primarily affected the operations of our North American and European dental and medical distribution businesses. Henry Schein One, our practice management software, revenue cycle management and patient relationship management solutions business, was not affected, and our manufacturing businesses were mostly unaffected. On November 22, 2023, we experienced a disruption of our ecommerce platform and related applications, which was remediated.

During the three and nine months ended September 28, 2024, we had a sales decrease in our dental and medical distribution businesses, which we believe was primarily a result of lower sales to episodic customers following last year's cyber incident. We have a number of programs underway focused on re-establishing these customers.

We maintain cyber insurance, subject to certain retentions and policy limitations. With respect to the October 2023 cyber incident, we have a \$60 million insurance policy, following a \$5 million retention. During the three and nine months ended September 28, 2024, we received insurance proceeds of \$10 million and \$20 million, respectively, representing a partial insurance recovery of losses related to the cyber incident.

## **Executive-Level Overview**

Henry Schein, Inc. is a solutions company for health care professionals powered by a network of people and technology. We believe we are the world's largest provider of health care products and services primarily to office-based dental and medical practitioners, as well as alternate sites of care. We serve more than one million customers worldwide including dental practitioners, laboratories, physician practices and ambulatory surgery centers, as well as government, institutional health care clinics and other alternate care clinics. We believe that we have a strong brand identity due to our more than 92 years of experience distributing health care products.

We are headquartered in Melville, New York, employ approximately 26,000 people (of which approximately 13,000 are based outside of the United States) and have operations or affiliates in 33 countries and territories. Our broad global footprint has evolved over time through our organic success as well as through contribution from strategic acquisitions.

We have established strategically located distribution centers around the world to enable us to better serve our customers and increase our operating efficiency. This infrastructure, together with broad product and service offerings at competitive prices, and a strong commitment to customer service, enables us to be a single source of supply for our customers' needs.

While our primary go-to-market strategy is in our capacity as a distributor, we also market and sell our own corporate brand portfolio of cost-effective, high-quality consumable merchandise products, including in vitro diagnostic devices, manufacture certain dental specialty products in the areas of implants, orthodontics and endodontics, manufacture drug products, and repackage/relabel prescription drugs and/or devices. We have achieved scale in these global businesses primarily through acquisitions, as manufacturers of these products typically do not utilize a distribution channel to serve customers.

We conduct our business through two reportable segments: (i) health care distribution and (ii) technology and value-added services. These segments offer different products and services to the same customer base. Our global dental businesses serve office-based dental practitioners, dental laboratories, schools, government and other institutions. Our medical businesses serve physician offices, urgent care centers, ambulatory care sites, emergency medical technicians, dialysis centers, home health, federal and state governments and large enterprises, such as group practices, and integrated delivery networks, among other providers across a wide range of specialties.

The health care distribution reportable segment, combining our global dental and medical operating segments, distributes consumable products, small equipment, laboratory products, large equipment, equipment repair services, branded and generic pharmaceuticals, vaccines, surgical products, dental specialty products (including implant, orthodontic and endodontic products), diagnostic tests, infection-control products, personal protective equipment ("PPE") products, vitamins and orthopedic implants.

Our global technology and value-added services business provides software, technology and other value-added services to health care practitioners. Our technology business offerings include practice management software systems for dental and medical practitioners. Our value-added practice solutions include practice consultancy, education, revenue cycle management and financial services on a non-recourse basis, e-services, practice technology, network and hardware services, as well as consulting, and continuing education services for practitioners.

A key element to grow closer to our customers is our One Schein initiative, which is a unified go-to-market approach that enables practitioners to work synergistically with our supply chain, equipment sales and service and other value-added services, allowing our customers to leverage the combined value that we offer through a single program. Specifically, One Schein provides customers with streamlined access to our comprehensive offering of national brand products, our corporate brand products and proprietary specialty products and solutions (including implant, orthodontic and endodontic products). In addition, customers have access to a wide range of services, including software and other value-added services.



## [Table of Contents](#)

### *Industry Overview*

In recent years, the health care industry has increasingly focused on cost containment. This trend has benefited distributors capable of providing a broad array of products and services at low prices. It also has accelerated the growth of HMOs, group practices, other managed care accounts and collective buying groups, which, in addition to their emphasis on obtaining products at competitive prices, tend to favor distributors capable of providing specialized management information support. We believe that the trend towards cost containment has the potential to favorably affect demand for technology solutions, including software, which can enhance the efficiency and facilitation of practice management.

Our operating results in recent years have been significantly affected by strategies and transactions that we undertook to expand our business, domestically and internationally, in part to address significant changes in the health care industry, including consolidation of health care distribution companies, health care reform, trends toward managed care, cuts in Medicare and collective purchasing arrangements.

### *Industry Consolidation*

The health care products distribution industry, as it relates to office-based health care practitioners, is fragmented and diverse. The industry ranges from sole practitioners working out of relatively small offices to group practices or service organizations ranging in size from a few practitioners to a large number of practitioners who have combined or otherwise associated their practices.

Due in part to the inability of office-based health care practitioners to store and manage large quantities of supplies in their offices, the distribution of health care supplies and small equipment to office-based health care practitioners has been characterized by frequent, small quantity orders, and a need for rapid, reliable and substantially complete order fulfillment. The purchasing decisions within an office-based health care practice are typically made by the practitioner or an administrative assistant. Supplies and small equipment are generally purchased from more than one distributor, with one generally serving as the primary supplier.

The trend of consolidation extends to our customer base. Health care practitioners are increasingly seeking to partner, affiliate or combine with larger entities such as hospitals, health systems, group practices or physician hospital organizations. In many cases, purchasing decisions for consolidated groups are made at a centralized or professional staff level; however, orders are delivered to the practitioners' offices.

We believe that consolidation within the industry will continue to result in a number of distributors, particularly those with limited financial, operating and marketing resources, seeking to combine with larger companies that can provide growth opportunities. This consolidation also may continue to result in distributors seeking to acquire companies that can enhance their current product and service offerings or provide opportunities to serve a broader customer base.

Our approach to acquisitions and joint ventures has been to expand our role as a provider of products and services to the health care industry. This trend has resulted in our expansion into service areas that complement our existing operations and provide opportunities for us to develop synergies with, and thus strengthen, the acquired businesses.

As industry consolidation continues, we believe that we are positioned to capitalize on this trend, as we believe we have the ability to support increased sales through our existing infrastructure, although there can be no assurances that we will be able to successfully accomplish this. We are focused on building relationships with decision makers who do not reside in the office-based practitioner setting.

As the health care industry continues to change, we continually evaluate possible candidates for joint venture or acquisition and intend to continue to seek opportunities to expand our role as a provider of products and services to the health care industry. There can be no assurance that we will be able to successfully pursue any such opportunity or consummate any such transaction, if pursued. If additional transactions are entered into or consummated, we would incur merger and/or acquisition-related costs, and there can be no assurance that the integration efforts associated with any such transaction would be successful.



### *Aging Population and Other Market Influences*

The health care products distribution industry continues to experience growth due to the aging population, increased health care awareness, the proliferation of medical technology and testing, new pharmacological treatments, and expanded third-party insurance coverage, partially offset by the effects of unemployment on insurance coverage. In addition, the physician market continues to benefit from the shift of procedures and diagnostic testing from acute care settings to alternate-care sites, particularly physicians' offices.

According to the U.S. Census Bureau's International Database, between 2024 and 2034, the 45 and older population is expected to grow by approximately 11%. Between 2024 and 2044, this age group is expected to grow by approximately 20%. This compares with expected total U.S. population growth rates of approximately 6% between 2024 and 2034 and approximately 11% between 2024 and 2044.

According to the U.S. Census Bureau's International Database, in 2024 there are approximately seven million Americans aged 85 years or older, the segment of the population most in need of long-term care and elder-care services. By the year 2050, that number is projected to nearly triple to approximately 19 million. The population aged 65 to 84 years is projected to increase by approximately 20% during the same period.

As a result of these market dynamics, annual expenditures for health care services continue to increase in the United States. We believe that demand for our products and services will grow while continuing to be impacted by current and future operating, economic, and industry conditions. The Centers for Medicare and Medicaid Services ("CMS") published "National Health Expenditure Data" indicating that total national health care spending reached approximately \$4.5 trillion in 2022, or 17.3% of the nation's gross domestic product, the benchmark measure for annual production of goods and services in the United States. Health care spending is projected to reach approximately \$7.7 trillion by 2032, or 19.7% of the nation's projected gross domestic product.

### *Government*

Certain of our businesses involve the distribution, manufacturing, importation, exportation, marketing, sale and promotion of pharmaceuticals and/or medical devices, and in this regard, we are subject to extensive local, state, federal and foreign governmental laws and regulations, including as applicable to our wholesale distribution of pharmaceuticals and medical devices, manufacturing activities, and as part of our specialty home medical supply businesses that distribute and sell medical equipment and supplies directly to patients. Federal, state and certain foreign governments have also increased enforcement activity in the health care sector, particularly in areas of fraud and abuse, anti-bribery and anti-corruption, controlled substances handling, medical device regulations and data privacy and security standards.

Certain of our businesses involve pharmaceuticals and/or medical devices, including in vitro diagnostic devices, that are paid for by third parties and must operate in compliance with a variety of burdensome and complex coding, billing and record-keeping requirements in order to substantiate claims for payment under federal, state and commercial healthcare reimbursement programs.

Government and private insurance programs fund a large portion of the total cost of medical care, and there have been efforts to limit such private and government insurance programs, including efforts, thus far unsuccessful, to seek repeal of the entire United States Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act, each enacted in March 2010.

Certain of our businesses are subject to various additional federal, state, local and foreign laws and regulations, including with respect to the sale, transportation, importation, storage, handling and disposal of hazardous or potentially hazardous substances; "forever chemicals" such as per-and polyfluoroalkyl substances; amalgam bans; pricing disclosures; supply chain transparency around labor practices; and safe working conditions. In addition, activities to control medical costs, including laws and regulations lowering reimbursement rates for pharmaceuticals, medical devices, medical supplies and/or medical treatments or services, are ongoing. CMS recently released the 2024 durable medical equipment, prosthetics, orthotics and supplies ("DMEPOS")

## [Table of Contents](#)

reimbursement schedule, which, effective January 1, 2024, reduced the DMEPOS reimbursement rates for non-rural suppliers, such as us, by removing the Coronavirus Aid, Relief, and Economic Security (aka CARES) Act relief rates in effect during the COVID-19 pandemic. This and other laws and regulations are subject to change and their evolving implementation may impact our operations and our financial performance.

Our businesses are generally subject to numerous laws and regulations that could impact our financial performance, and failure to comply with such laws or regulations could have a material adverse effect on our business.

A more detailed discussion of governmental laws and regulations is included in Management's Discussion & Analysis of Financial Condition and Results of Operations, contained in our Annual Report on Form 10-K for the fiscal year ended December 30, 2023, filed with the SEC on February 28, 2024.

### Results of Operations

The following tables summarize the significant components of our operating results for the three and nine months ended September 28, 2024 and September 30, 2023 and cash flows for the nine months ended September 28, 2024 and September 30, 2023:

	Three Months Ended		Nine Months Ended	
	September 28, 2024	September 30, 2023	September 28, 2024	September 30, 2023
<b>Operating results:</b>				
Net sales	\$ 3,174	\$ 3,162	\$ 9,482	\$ 9,322
Cost of sales	2,181	2,167	6,459	6,386
Gross profit	993	995	3,023	2,936
Operating expenses:				
Selling, general and administrative	724	725	2,296	2,149
Depreciation and amortization	64	59	188	152
Restructuring costs	48	11	73	59
Operating income	<u>\$ 157</u>	<u>\$ 200</u>	<u>\$ 466</u>	<u>\$ 576</u>
Other expense, net	\$ (29)	\$ (21)	\$ (79)	\$ (48)
Net income	99	143	302	419
Net income attributable to Henry Schein, Inc.	99	137	296	398

	Nine Months Ended	
	September 28, 2024	September 30, 2023
<b>Cash flows:</b>		
Net cash provided by operating activities	\$ 644	\$ 532
Net cash used in investing activities	(372)	(808)
Net cash provided by (used in) financing activities	(306)	307

## **Plans of Restructuring**

On August 1, 2022, we committed to a restructuring plan (the “2022 Plan”) focused on funding the priorities of the BOLD+1 strategic plan, streamlining operations and other initiatives to increase efficiency. The 2022 Plan has been completed as of July 31, 2024. During the three months ended September 28, 2024 and September 30, 2023, in connection with our 2022 Plan, we recorded restructuring costs of \$12 million and \$11 million, respectively. During the nine months ended September 28, 2024 and September 30, 2023, in connection with our 2022 Plan, we recorded restructuring costs of \$37 million and \$59 million, respectively. The restructuring costs for these periods primarily related to severance and employee-related costs, accelerated amortization of right-of-use lease assets and fixed assets, and other exit costs. We expect to record immaterial charges associated with the 2022 Plan during the remainder of 2024.

On August 6, 2024, we committed to a new restructuring plan (the “2024 Plan”) to integrate recent acquisitions, right-size operations and further increase efficiencies. During the three and nine months ended September 28, 2024, we recorded restructuring charges associated with the 2024 Plan of \$36 million which primarily related to severance and employee-related costs, accelerated amortization of right-of-use lease assets and fixed assets, and other lease exit costs. We expect to record restructuring charges associated with the 2024 Plan during the fourth quarter of 2024 and in 2025, however an estimate of the amount of these charges has not yet been determined.

[Table of Contents](#)

**Three Months Ended September 28, 2024 Compared to Three Months Ended September 30, 2023**

Note: Percentages for Net Sales; Gross Profit; Operating Expenses; Other Expense, Net; and Income Taxes are based on actual values and may not recalculate due to rounding.

**Net Sales**

Net sales were as follows:

	September 28, 2024	% of Total	September 30, 2023	% of Total	Increase / (Decrease)	
					\$	%
Health care distribution <sup>(1)</sup>						
Dental	\$ 1,852	58.4%	\$ 1,882	59.5%	\$ (30)	(1.6)%
Medical	1,101	34.7	1,070	33.9	31	2.9
Total health care distribution	2,953	93.1	2,952	93.4	1	-
Technology and value-added services <sup>(2)</sup>	221	6.9	210	6.6	11	5.1
Total	<u>\$ 3,174</u>	<u>100.0%</u>	<u>\$ 3,162</u>	<u>100.0%</u>	<u>\$ 12</u>	<u>0.4%</u>

The components of our sales growth were as follows:

	Local Currency Growth		Total Local Currency Growth	Foreign Exchange Impact	Total Sales Growth
	Local Internal Growth	Acquisition Growth			
Health care distribution <sup>(1)</sup>					
Dental Merchandise	(2.5)%	0.3 %	(2.2)%	(0.6)%	(2.8)%
Dental Equipment	1.8	0.9	2.7	0.1	2.8
Total Dental	(1.6)	0.5	(1.1)	(0.5)	(1.6)
Medical	(4.8)	7.6	2.8	0.1	2.9
Total Health Care Distribution	(2.7)	3.0	0.3	(0.3)	-
Technology and value-added services <sup>(2)</sup>	(1.1)	6.0	4.9	0.2	5.1
Total	(2.6)%	3.2 %	0.6 %	(0.2)%	0.4 %

- (1) Consists of consumable products, dental specialty products (including implant, orthodontic and endodontic products), small equipment, laboratory products, large equipment, equipment repair services, branded and generic pharmaceuticals, vaccines, surgical products, diagnostic tests, infection-control products, PPE products, vitamins and orthopedic implants.
- (2) Consists of practice management software and other value-added products, which are distributed primarily to health care providers, practice consultancy, education, revenue cycle management and financial services on a non-recourse basis, e-services, continuing education services for practitioners, practice technology, network and hardware services, and other services.

**Global Sales**

Global net sales for the three months ended September 28, 2024 increased 0.4%. The components of our sales growth are presented in the table above.

The 2.6% decrease in our internally generated local currency sales was primarily attributable to the slower than anticipated pace of recovery from the cyber incident, the challenging economic environment in certain markets and lower sales of PPE products and COVID-19 test kits, partially offset by sales growth in dental equipment and dental specialty products. For the three months ended September 28, 2024, the estimated decrease in internally generated local currency sales, excluding PPE products and COVID-19 test kits, was 2.2%.

We estimate that sales of PPE products and COVID-19 test kits were approximately \$157 million and \$175 million for the three months ended September 28, 2024 and September 30, 2023, respectively, representing an estimated decrease of \$18 million, or 10.1% versus the prior year, with the \$18 million net decrease year-over-year representing 0.6% of global net sales for the three months ended September 28, 2024.

## [Table of Contents](#)

### *Dental*

Dental net sales for the three months ended September 28, 2024 decreased 1.6%. The components of our sales decline are presented in the table above.

The decrease in local currency sales was attributable to a 1.6% decrease in internally generated local currency sales of dental merchandise, partially offset by an increase in internally generated local currency sales of dental equipment and dental specialty products and sales from entities acquired during the twelve months ended September 28, 2024. The decrease in internally generated local currency sales of dental merchandise was primarily attributable to the slower than anticipated pace of recovery from the cyber incident, the challenging economic environment in certain markets, and lower sales of PPE products. The increase in internally generated local currency sales of dental equipment was primarily attributable to certain international markets and traditional equipment and our parts and service business in North America, partially offset by a decline in digital imaging in North America.

We estimate that sales of PPE products were approximately \$72 million and \$83 million for the three months ended September 28, 2024 and September 30, 2023, respectively, representing an estimated decrease of \$11 million, or 13.0% versus the prior year, with the \$11 million net decrease year-over-year representing 0.6% of dental net sales for the three months ended September 28, 2024. The decrease in sales of PPE products was primarily due to lower glove prices. The estimated decrease in internally generated local currency sales, excluding PPE products, was 1.0%.

### *Medical*

Medical net sales for the three months ended September 28, 2024 increased 2.9%. The components of our sales growth are presented in the table above.

The increase in local currency sales was attributable to our expansion in the Home Solutions market, including the acquisition of Shield Healthcare during the year ended December 30, 2023, and our acquisition of TriMed, Inc. during the second quarter of 2024, partially offset by a 4.8% decrease in internally generated local currency medical sales, resulting from the slower than anticipated pace of recovery from the cyber incident, the conversion of certain pharmaceutical products to lower priced generics, and lower sales of influenza vaccines, PPE products and COVID-19 test kits.

We estimate that sales of PPE products and COVID-19 test kits were approximately \$85 million and \$92 million for the three months ended September 28, 2024 and September 30, 2023, respectively, representing an estimated decrease of \$7 million, or 7.5% versus the prior year, with the \$7 million net decrease year-over-year representing 0.6% of medical net sales for the three months ended September 28, 2024. The decrease in sales of these products was primarily due to lower market prices of PPE products (primarily lower glove pricing). The estimated decrease in internally generated local currency sales, excluding PPE products and COVID-19 test kits, was 4.6%.

### *Technology and value-added services*

Technology and value-added services net sales for the three months ended September 28, 2024 increased 5.1%. The components of our sales growth are presented in the table above. The internally generated local currency increase in technology and value-added services sales was primarily attributable to entities acquired during the twelve months ended September 28, 2024, a continued increase in the number of cloud-based users of our practice management software and an increase in revenue cycle management solutions.

[Table of Contents](#)

**Gross Profit**

Gross profit and gross margin percentages by segment and in total were as follows:

	September 28,	Gross	September 30,	Gross	Increase / (Decrease)	
	2024	Margin %	2023	Margin %	\$	%
Health care distribution	\$ 844	28.6%	\$ 851	28.8%	\$ (7)	(0.9)%
Technology and value-added services	149	67.8	144	68.7	5	3.8
Total	<u>\$ 993</u>	<u>31.3</u>	<u>\$ 995</u>	<u>31.5</u>	<u>\$ (2)</u>	<u>(0.2)</u>

As a result of different practices of categorizing costs associated with distribution networks throughout our industry, our gross margins may not necessarily be comparable to other distribution companies. Additionally, we realize substantially higher gross margin percentages in our technology and value-added services segment than in our health care distribution segment. These higher gross margins result from being both the developer and seller of software products and services, as well as certain financial services. The software industry typically realizes higher gross margins to recover investments in product development.

Within our health care distribution segment, gross profit margins may vary between the periods as a result of the changes in the mix of products sold as well as changes in our customer mix. For example, sales of our corporate brand and certain specialty products achieve gross profit margins that are higher than average total gross profit margins of all products. With respect to customer mix, sales to our large-group customers are typically completed at lower gross margins due to the higher volumes sold as opposed to the gross margin on sales to office-based practitioners, who normally purchase lower volumes.

Health care distribution gross profit for the three months ended September 28, 2024 was relatively flat compared to the prior-year-period.

Technology and value-added services gross profit increased as a result of gross profit from acquisitions, partially offset by lower internally generated sales.

**Operating Expenses**

Operating expenses (consisting of selling, general and administrative expenses; depreciation and amortization; and restructuring costs) by segment and in total were as follows:

	September 28,	% of	September 30,	% of	Increase	
	2024	Respective Net Sales	2023	Respective Net Sales	\$	%
Health care distribution	\$ 726	24.6%	\$ 691	23.4%	\$ 35	5.1%
Technology and value-added services	110	50.1	104	49.7	6	6.0
Total	<u>\$ 836</u>	<u>26.3</u>	<u>\$ 795</u>	<u>25.1</u>	<u>\$ 41</u>	<u>5.2</u>

The net increase (decrease) in operating expenses is attributable to the following:

	Operating Costs	Restructuring Costs	Acquisitions	Total
Health care distribution	\$ (18)	\$ 28	\$ 25	\$ 35
Technology and value-added services	(6)	9	3	6
Total	<u>\$ (24)</u>	<u>\$ 37</u>	<u>\$ 28</u>	<u>\$ 41</u>

The components of the net increase in total operating expenses are presented in the table above. The increase in operating costs during the three months ended September 28, 2024 includes increases in payroll and payroll related costs in both of our reportable segments, as well as increased acquisition intangible amortization in our healthcare distribution segment, partially offset by a gain of \$19 million related to the remeasurement to fair value of a previously held equity investment within our healthcare distribution segment.

## [Table of Contents](#)

During the three months ended September 28, 2024, we also incurred \$1 million of expenses, within our health care distribution segment, directly related to the cyber incident, mostly consisting of professional fees. During the three months ended September 28, 2024, we received insurance proceeds of \$10 million, recorded as a reduction of selling, general and administrative expenses, representing a partial insurance recovery of losses related to the cyber incident.

### ***Other Expense, Net***

Other expense, net was as follows:

	September 28,	September 30,	Variance	
	2024	2023	\$	%
Interest income	\$ 7	\$ 6	\$ 1	(3.2)%
Interest expense	(34)	(25)	(9)	(31.9)
Other, net	(2)	(2)	-	(45.4)
Other expense, net	<u>\$ (29)</u>	<u>\$ (21)</u>	<u>\$ (8)</u>	(36.4)

Interest expense increased primarily due to increased borrowings and increased interest rates.

### ***Income Taxes***

Our effective tax rate was 24.7% for the three months ended September 28, 2024, compared to 21.9% for the prior year period. The difference between our effective and federal statutory tax rates primarily relates to state and foreign income taxes and interest expense.

The Organization of Economic Co-Operation and Development (OECD) issued technical and administrative guidance on Pillar Two rules in December 2021, which provides for a global minimum tax rate on the earnings of large multinational businesses on a country-by-country basis. Effective January 1, 2024, the minimum global tax rate is 15% for various jurisdictions pursuant to the Pillar Two rules. As of September 28, 2024, the impact of the Pillar Two rules to our financial statements was immaterial. As we operate in jurisdictions which have adopted Pillar Two, we are continuing to analyze the implications to effectively manage the impact for 2024 and beyond. Future tax reform resulting from these developments may result in changes to long-standing tax principles, which may adversely impact our effective tax rate going forward or result in higher cash tax liabilities.

[Table of Contents](#)

**Nine Months Ended September 28, 2024 Compared to Nine Months Ended September 30, 2023**

Note: Percentages for Net Sales; Gross Profit; Operating Expenses; Other Expense, Net; and Income Taxes are based on actual values and may not recalculate due to rounding.

**Net Sales**

Net sales were as follows:

	September 28,	% of	September 30,	% of	Increase / (Decrease)	
	2024	Total	2023	Total	\$	%
<b>Health care distribution <sup>(1)</sup></b>						
Dental	\$ 5,690	60.0%	\$ 5,737	61.5%	\$ (47)	(0.8)%
Medical	3,140	33.1	2,991	32.1	149	5.0
Total health care distribution	8,830	93.1	8,728	93.6	102	1.2
<b>Technology and value-added services <sup>(2)</sup></b>						
	652	6.9	594	6.4	58	9.7
Total	\$ 9,482	100.0%	\$ 9,322	100.0%	\$ 160	1.7%

The components of our sales growth were as follows:

	Local Currency Growth		Total Local Currency Growth	Foreign Exchange Impact	Total Sales Growth
	Local Internal Growth	Acquisition Growth			
<b>Health care distribution <sup>(1)</sup></b>					
Dental Merchandise	(3.0)%	1.9 %	(1.1)%	(0.2)%	(1.3)%
Dental Equipment	0.5	0.4	0.9	-	0.9
Total Dental	(2.2)	1.5	(0.7)	(0.1)	(0.8)
Medical	(3.3)	8.3	5.0	-	5.0
Total Health Care Distribution	(2.6)	3.9	1.3	(0.1)	1.2
<b>Technology and value-added services <sup>(2)</sup></b>					
	1.9	7.7	9.6	0.1	9.7
Total	(2.3)%	4.1 %	1.8 %	(0.1)%	1.7 %

- (1) Consists of consumable products, dental specialty products (including implant, orthodontic and endodontic products), small equipment, laboratory products, large equipment, equipment repair services, branded and generic pharmaceuticals, vaccines, surgical products, diagnostic tests, infection-control products, PPE products, vitamins and orthopedic implants.
- (2) Consists of practice management software and other value-added products, which are distributed primarily to health care providers, practice consultancy, education, revenue cycle management and financial services on a non-recourse basis, e-services, continuing education services for practitioners, practice technology, network and hardware services, and other services.

**Global Sales**

Global net sales for the nine months ended September 28, 2024 increased 1.7%. The components of our sales growth are presented in the table above.

The 2.3% decrease in our internally generated local currency sales was primarily attributable to the slower than anticipated pace of recovery from the cyber incident, the challenging economic environment in certain markets and lower sales of PPE products. For the nine months ended September 28, 2024, the estimated decrease in internally generated local currency sales, excluding PPE products and COVID-19 test kits, was 1.7%.

We estimate that sales of PPE products and COVID-19 test kits were approximately \$478 million and \$540 million for the nine months ended September 28, 2024 and September 30, 2023, respectively, representing an estimated decrease of \$62 million, or 11.3% versus the prior year, with the \$62 million net decrease year-over-year representing 0.6% of global net sales for the nine months ended September 28, 2024.



## [Table of Contents](#)

### *Dental*

Dental net sales for the nine months ended September 28, 2024 decreased 0.8%. The components of our sales decline are presented in the table above.

The decrease in local currency sales was attributable to a decrease in internally generated local currency sales for dental merchandise of 2.2%, partially offset by sales growth in internally generated local currency sales for dental equipment and dental specialty products. The decrease in internally generated local currency sales of dental merchandise was primarily attributable to the slower than anticipated pace of recovery from the cyber incident, the challenging economic environment in certain markets, and lower sales of PPE products. Our sales growth in internally generated local currency sales for dental equipment was primarily due to growth in North America for traditional equipment and our parts and service business, partially offset by lower North American digital equipment sales and declines in certain international markets, and some sales shifting into the first quarter of 2024 due to the delay of equipment installations during the fourth quarter of 2023 resulting from the impact of the cyber incident.

We estimate that sales of PPE products were approximately \$228 million and \$264 million for the nine months ended September 28, 2024 and September 30, 2023, respectively, representing an estimated decrease of \$36 million, or 13.4% versus the prior year, with the \$36 million net decrease year-over-year representing 0.6% of dental net sales for the nine months ended September 28, 2024. The decrease in sales of PPE products was primarily due to lower glove prices and reduced demand following the cyber incident. The estimated decrease in internally generated local currency sales, excluding PPE products, was 1.6%.

### *Medical*

Medical net sales for the nine months ended September 28, 2024 increased 5.0%. The components of our sales growth are presented in the table above.

The increase in local currency sales was attributable to our expansion in the Home Solutions market, including the acquisition of Shield Healthcare during the year ended December 30, 2023, offset by a decrease of 3.3% in internally generated local currency medical sales, resulting from the slower than anticipated pace of recovery from the cyber incident, the conversion of certain pharmaceutical products to lower priced generics, and lower sales of PPE products and influenza vaccines, partially offset by strong sales of point-of-care diagnostics including multi-assay flu/COVID combination test kits.

We estimate that sales of PPE products and COVID-19 test kits were approximately \$250 million and \$276 million for the nine months ended September 28, 2024 and September 30, 2023, respectively, representing an estimated decrease of \$26 million, or 9.4% versus the prior year, with the \$26 million net decrease year-over-year representing 0.8% of medical net sales for the nine months ended September 28, 2024. The decrease in sales of these products was primarily due to lower market prices of PPE products (primarily lower glove pricing). The estimated decrease in internally generated local currency sales, excluding PPE products and COVID-19 test kits, was 2.6%.

### *Technology and value-added services*

Technology and value-added services net sales for the nine months ended September 28, 2024 increased 9.7%. The components of our sales growth are presented in the table above. The internally generated local currency increase of 1.9% in technology and value-added services sales was primarily attributable to a continued increase in the number of cloud-based users of our practice management software and an increase in revenue cycle management solutions and our analytical products.

[Table of Contents](#)

**Gross Profit**

Gross profit and gross margin percentages by segment and in total were as follows:

	September 28,	Gross	September 30,	Gross	Increase	
	2024	Margin %	2023	Margin %	\$	%
Health care distribution	\$ 2,586	29.3%	\$ 2,534	29.0%	\$ 52	2.0 %
Technology and value-added services	437	67.1	402	67.6	35	8.8
Total	<u>\$ 3,023</u>	31.9	<u>\$ 2,936</u>	31.5	<u>\$ 87</u>	2.9

As a result of different practices of categorizing costs associated with distribution networks throughout our industry, our gross margins may not necessarily be comparable to other distribution companies. Additionally, we realize substantially higher gross margin percentages in our technology and value-added services segment than in our health care distribution segment. These higher gross margins result from being both the developer and seller of software products and services, as well as certain financial services. The software industry typically realizes higher gross margins to recover investments in product development.

Within our health care distribution segment, gross profit margins may vary between the periods as a result of the changes in the mix of products sold as well as changes in our customer mix. For example, sales of our corporate brand and certain specialty products achieve gross profit margins that are higher than average total gross profit margins of all products. With respect to customer mix, sales to our large-group customers are typically completed at lower gross margins due to the higher volumes sold as opposed to the gross margin on sales to office-based practitioners, who normally purchase lower volumes.

Health care distribution gross profit for the nine months ended September 28, 2024 increased compared to the prior-year-period due to gross profit from acquisitions and gross margin expansion as a result of a favorable impact of sales mix of higher-margin products.

Technology and value-added services gross profit increased as a result of a higher gross profit from internally generated sales and gross profit from acquisitions.

**Operating Expenses**

Operating expenses (consisting of selling, general and administrative expenses; depreciation and amortization; and restructuring costs) by segment and in total were as follows:

	September 28,	% of	September 30,	% of	Increase	
	2024	Respective Net Sales	2023	Respective Net Sales	\$	%
Health care distribution	\$ 2,196	24.9%	\$ 2,063	23.6%	\$ 133	6.5%
Technology and value-added services	361	55.4	297	50.1	64	21.4
Total	<u>\$ 2,557</u>	27.0	<u>\$ 2,360</u>	25.3	<u>\$ 197</u>	8.3

The net increase in operating expenses is attributable to the following:

	Operating Costs	Restructuring Costs	Acquisitions	Total
Health care distribution	\$ 11	\$ 9	\$ 113	\$ 133
Technology and value-added services	44	5	15	64
Total	<u>\$ 55</u>	<u>\$ 14</u>	<u>\$ 128</u>	<u>\$ 197</u>

The components of the net increase in total operating expenses are presented in the table above. The increase in operating costs during the nine months ended September 28, 2024 includes increases in payroll and payroll related costs, travel, convention expenses and litigation settlement costs in both of our reportable segments, as well as increased acquisition intangible amortization in our healthcare distribution segment, partially offset by a gain of \$19 million related to the remeasurement to fair value of a previously held equity investment within our healthcare

## [Table of Contents](#)

distribution segment. The impact from this remeasurement gain was similar to that of a remeasurement gain related to another buy-up of a business within our healthcare distribution segment during the nine months ended September 30, 2023.

We also recorded an increase of \$38 million in accrued contingent consideration related to a 2023 acquisition in our technology and value-added services segment. During the nine months ended September 28, 2024, we also incurred \$12 million of expenses, within our health care distribution segment, directly related to the cyber incident, mostly consisting of professional fees. During the nine months ended September 28, 2024, we received insurance proceeds of \$20 million, recorded as a reduction of selling, general and administrative expenses, representing a partial insurance recovery of losses related to the cyber incident.

### ***Other Expense, Net***

Other expense, net was as follows:

	September 28,	September 30,	Variance	
	2024	2023	\$	%
Interest income	\$ 18	\$ 12	\$ 6	44.7%
Interest expense	(96)	(58)	(38)	(64.7)
Other, net	(1)	(2)	1	(82.4)
Other expense, net	<u>\$ (79)</u>	<u>\$ (48)</u>	<u>\$ (31)</u>	(63.8)

Interest income increased primarily due to increased interest rates. Interest expense increased primarily due to increased borrowings and increased interest rates.

### ***Income Taxes***

Our effective tax rate was 25.1% for the nine months ended September 28, 2024, compared to 22.5% for the prior year period. The difference between our effective and federal statutory tax rates primarily relates to state and foreign income taxes and interest expense.

The Organization of Economic Co-Operation and Development (OECD) issued technical and administrative guidance on Pillar Two rules in December 2021, which provides for a global minimum tax rate on the earnings of large multinational businesses on a country-by-country basis. Effective January 1, 2024, the minimum global tax rate is 15% for various jurisdictions pursuant to the Pillar Two rules. As of September 28, 2024, the impact of the Pillar Two rules to our financial statements was immaterial. As we operate in jurisdictions which have adopted Pillar Two, we are continuing to analyze the implications to effectively manage the impact for 2024 and beyond. Future tax reform resulting from these developments may result in changes to long-standing tax principles, which may adversely impact our effective tax rate going forward or result in higher cash tax liabilities.

## Liquidity and Capital Resources

Our principal capital requirements have included funding of acquisitions, purchases of additional noncontrolling interests, repayments of debt principal, the funding of working capital needs, purchases of fixed assets and repurchases of common stock. Working capital requirements generally result from increased sales, special inventory forward buy-in opportunities and payment terms for receivables and payables. Historically, sales have tended to be stronger during the second half of the year and special inventory forward buy-in opportunities have been most prevalent just before the end of the year, and have caused our working capital requirements to be higher from the end of the third quarter to the end of the first quarter of the following year.

We finance our business primarily through cash generated from our operations, revolving credit facilities and debt placements. Please see [Note 8 – Debt](#) for further information. Our ability to generate sufficient cash flows from operations is dependent on the continued demand of our customers for our products and services, and access to products and services from our suppliers.

Our business requires a substantial investment in working capital, which is susceptible to fluctuations during the year as a result of inventory purchase patterns and seasonal demands. Inventory purchase activity is a function of sales activity, special inventory forward buy-in opportunities and our desired level of inventory. We anticipate future increases in our working capital requirements.

We finance our business to provide adequate funding for at least 12 months. Funding requirements are based on forecasted profitability and working capital needs, which, on occasion, may change. Consequently, we may change our funding structure to reflect any new requirements.

We believe that our cash and cash equivalents, our ability to access private debt markets and public equity markets, and our available funds under existing credit facilities provide us with sufficient liquidity to meet our currently foreseeable short-term and long-term capital needs.

Our acquisition strategy is focused on investments in companies that add new customers and sales teams, increase our geographic footprint (whether entering a new country, such as emerging markets, or building scale where we have already invested in businesses), and finally, those that enable us to access new products and technologies.

Net cash provided by operating activities was \$644 million for the nine months ended September 28, 2024, compared to net cash provided by operating activities of \$532 million for the prior year. The net change of \$112 million was primarily attributable to changes in working capital accounts, primarily accounts receivable and inventory; partially offset by lower cash net income. During the nine months ended September 28, 2024, the cyber incident had several residual impacts to the operating cash flows from our working capital, net of acquisitions, including an increase in operating cash flows from accounts receivable due to improved collection levels and decreased cash flows from accounts payable and accrued expenses resulting from previously delayed payments.

Net cash used in investing activities was \$372 million for the nine months ended September 28, 2024, compared to net cash used in investing activities of \$808 million for the prior year. The net change of \$436 million was primarily attributable to decreased payments for equity investments and business acquisitions.

Net cash used in financing activities was \$306 million for the nine months ended September 28, 2024, compared to net cash provided by financing activities of \$307 million for the prior year. The net change of \$613 million was primarily due to decreased net borrowings from debt to finance our investments and increased acquisitions of noncontrolling interests in subsidiaries and increased repurchases of common stock.

## [Table of Contents](#)

The following table summarizes selected measures of liquidity and capital resources:

	September 28, 2024	December 30, 2023
Cash and cash equivalents	\$ 126	\$ 171
Working capital <sup>(1)</sup>	1,218	1,805
Debt:		
Bank credit lines	\$ 638	\$ 264
Current maturities of long-term debt	109	150
Long-term debt	1,906	1,937
Total debt	<u>\$ 2,653</u>	<u>\$ 2,351</u>
Leases:		
Current operating lease liabilities	\$ 77	\$ 80
Non-current operating lease liabilities	262	310

(1) Includes \$341 million and \$284 million of certain accounts receivable which serve as security for U.S. trade accounts receivable securitization at September 28, 2024 and December 30, 2023, respectively.

Our cash and cash equivalents consist of bank balances and investments in money market funds representing overnight investments with a high degree of liquidity.

### *Accounts receivable days sales outstanding and inventory turns*

Our accounts receivable days sales outstanding from operations increased to 48.6 days as of September 28, 2024 from 43.7 days as of September 30, 2023, which was primarily attributable to the impact of the cyber incident. During the nine months ended September 28, 2024, we wrote off approximately \$7 million of fully reserved accounts receivable against our trade receivable reserve. Our inventory turns from operations increased to 5.0 as of September 28, 2024 from 4.5 as of September 30, 2023. Our working capital accounts may be impacted by current and future economic conditions.

### *Leases*

We have operating and finance leases for corporate offices, office space, distribution and other facilities, vehicles and certain equipment. Our leases have remaining terms of approximately one year to approximately 17 years, some of which may include options to extend the leases for up to 15 years. As of September 28, 2024, our right-of-use assets related to operating leases were \$304 million and our current and non-current operating lease liabilities were \$77 million and \$262 million, respectively.

### *Stock Repurchases*

On July 31, 2024 our Board of Directors authorized the repurchase of up to an additional \$500 million in shares of our common stock.

From March 3, 2003 through September 28, 2024, we repurchased \$5.1 billion, or 94,763,315 shares, under our common stock repurchase programs, with \$455 million available as of September 28, 2024 for future common stock share repurchases. Subject to market conditions and other factors, we plan to continue to accelerate our share repurchase activity in light of our favorable cash position.

### *Redeemable Noncontrolling Interests*

Some minority stockholders in certain of our subsidiaries have the right, at certain times, to require us to acquire their ownership interest in those entities at fair value. Accounting Standards Codification Topic 480-10 is applicable for noncontrolling interests where we are or may be required to purchase all or a portion of the outstanding interest in a consolidated subsidiary from the noncontrolling interest holder under the terms of a put option contained in contractual agreements. As of September 28, 2024 and December 30, 2023, our balance for

[Table of Contents](#)

redeemable noncontrolling interests was \$832 million and \$864 million, respectively. Please see [Note 13 – Redeemable Noncontrolling Interests](#) for further information.

**Critical Accounting Policies and Estimates**

There have been no material changes in our critical accounting policies and estimates from those disclosed in Item 7 of our Annual Report on Form 10-K for the year ended December 30, 2023.

**Accounting Standards Update**

For a discussion of accounting standards updates that have been adopted or will be adopted, see [Note 2 - Significant Accounting Policies and Recently Issued Accounting Standards](#) of the Notes to the Condensed Consolidated Financial Statements included under Item 1.

**ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK**

There have been no material changes in our exposure to market risk from that disclosed in Item 7A of our Annual Report on Form 10-K for the year ended December 30, 2023.

## ITEM 4. CONTROLS AND PROCEDURES

### *Evaluation of Disclosure Controls and Procedures*

Under the supervision and with the participation of management, including our principal executive officer and principal financial officer, we evaluated the effectiveness of the design and operation of our disclosure controls and procedures as of the end of the period covered by this quarterly report as such term is defined in Rules 13a-15(e) and 15d-15(e) promulgated under the Securities Exchange Act of 1934, as amended (the “Exchange Act”). Based on this evaluation, our management, including our principal executive officer and principal financial officer, concluded that our disclosure controls and procedures were effective as of September 28, 2024, to ensure that all material information required to be disclosed by us in reports that we file or submit under the Exchange Act is accumulated and communicated to them as appropriate to allow timely decisions regarding required disclosure and that all such information is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms, and the rules of the Nasdaq stock exchange.

### *Changes in Internal Control over Financial Reporting*

The combination of acquisitions, including the acquisition of TriMed Inc. (“TriMed”), continued acquisition integrations and systems implementation activity undertaken during the quarter and carried over from prior quarters when considered in the aggregate, represents a material change in our internal control over financial reporting. As previously reported, the full integration of TriMed will extend beyond year-end and, therefore, we anticipate excluding TriMed from our annual assessment of internal control over financial reporting as of December 28, 2024, as permitted by related SEC staff interpretive guidance for newly acquired businesses.

During the quarter ended September 28, 2024, we completed the acquisition of a dental distribution business and acquired a controlling interest of a dental affiliate in Europe. Also, post-acquisition integration related activities continued for our dental and medical businesses acquired during prior quarters. These acquisitions, the majority of which utilize separate information and financial accounting systems, have been included in our condensed consolidated financial statements since their respective dates of acquisition.

Also, during the quarter ended September 28, 2024, we completed the systems implementation activities for implementing a new e-commerce system for certain dental distribution businesses in the UK and Ireland. Additionally, we completed the systems implementation activities related to the integration of a previously acquired Australian medical distribution business into our existing Australian ERP system. Finally, we continued systems implementation activities for two of our dental distribution businesses in France and Brazil.

All acquisitions, continued acquisition integrations and systems implementation activities involve necessary and appropriate change-management controls that are considered in our quarterly assessment of the design and operating effectiveness of our internal control over financial reporting.

The deficiencies in internal control over financial reporting identified as of December 30, 2023 at the application control level related to logical and user access management and segregation of duties have continued to be the subject of ongoing remediation including implementation of specific action plans and the testing/validation of control operating effectiveness, which are expected to be substantially completed prior to year-end.

### *Limitations of the Effectiveness of Internal Control*

A control system, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the internal control system are met. Because of the inherent limitations of any internal control system, no evaluation of controls can provide absolute assurance that all control issues, if any, within a company have been detected.

## PART II. OTHER INFORMATION

### ITEM 1. LEGAL PROCEEDINGS

For a discussion of Legal Proceedings, see [Note 11–Legal Proceedings](#) of the Notes to the Condensed Consolidated Financial Statements included under Item 1.

### ITEM 1A. RISK FACTORS

There have been no material changes from the risk factors disclosed in Part 1, Item 1A, of our Annual Report on Form 10-K for the year ended December 30, 2023.

### ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

#### *Purchases of equity securities by the issuer*

Our share repurchase program, announced on March 3, 2003, originally allowed us to repurchase up to two million shares pre-stock splits (eight million shares post-stock splits) of our common stock, which represented approximately 2.3% of the shares outstanding at the commencement of the program. Subsequent additional increases totaling \$4.9 billion, authorized by our Board of Directors, to the repurchase program provide for a total of \$5.5 billion (including \$500 million authorized on July 31, 2024) of shares of our common stock to be repurchased under this program.

As of September 28, 2024, we had repurchased approximately \$5.1 billion of common stock (94,763,315 shares) under these initiatives, with \$455 million available for future common stock share repurchases.

The following table summarizes repurchases of our common stock under our stock repurchase program during the fiscal quarter ended September 28, 2024:

<b>Fiscal Month</b>	<b>Total Number of Shares Purchased (1)</b>	<b>Average Price Paid Per Share</b>	<b>Total Number of Shares Purchased as Part of Our Publicly Announced Program</b>	<b>Maximum Number of Shares that May Yet Be Purchased Under Our Program (2)</b>
6/30/2024 through 8/3/2024	486,030	\$ 68.56	486,030	7,837,251
8//2024 through 8/31/2024	1,063,515	69.14	1,063,515	6,847,137
9/1/2024 through 9/28/2024	404,531	69.56	404,531	6,213,125
	<u>1,954,076</u>		<u>1,954,076</u>	

(1) All repurchases were executed in the open market under our existing publicly announced authorized program.

(2) The maximum number of shares that may yet be purchased under this program is determined at the end of each month based on the closing price of our common stock at that time. This table excludes shares withheld from employees to satisfy minimum tax withholding requirements for equity-based transactions.



[Table of Contents](#)

**ITEM 6. EXHIBITS**

<a href="#">31.1</a>	<a href="#">Certification Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.+</a>
<a href="#">31.2</a>	<a href="#">Certification Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.+</a>
<a href="#">32.1</a>	<a href="#">Certification Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.+</a>
<a href="#">101.INS</a>	<a href="#">Inline XBRL Instance Document - the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document+.</a>
<a href="#">101.SCH</a>	<a href="#">Inline XBRL Taxonomy Extension Schema Document+.</a>
<a href="#">101.CAL</a>	<a href="#">Inline XBRL Taxonomy Extension Calculation Linkbase Document+.</a>
<a href="#">101.DEF</a>	<a href="#">Inline XBRL Taxonomy Extension Definition Linkbase Document+.</a>
<a href="#">101.LAB</a>	<a href="#">Inline XBRL Taxonomy Extension Label Linkbase Document+.</a>
<a href="#">101.PRE</a>	<a href="#">Inline XBRL Taxonomy Extension Presentation Linkbase Document+.</a>
<a href="#">104</a>	<a href="#">The cover page of Henry Schein, Inc.'s Quarterly Report on Form 10-Q for the quarter ended September 28, 2024, formatted in Inline XBRL (included within Exhibit 101 attachments).+.</a>

+ Filed or furnished herewith.

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this Report to be signed on its behalf by the undersigned thereunto duly authorized.

Henry Schein, Inc.  
(Registrant)

By: /s/ Ronald N. South

Ronald N. South  
Senior Vice President and  
Chief Financial Officer  
(Authorized Signatory and Principal Financial  
and Accounting Officer)

Dated: November 5, 2024

**CERTIFICATION PURSUANT TO RULE 13a-14(a) OR 15d-14(a) OF THE SECURITIES  
EXCHANGE ACT OF 1934, AS ADOPTED PURSUANT TO SECTION 302 OF THE  
SARBANES-OXLEY ACT OF 2002**

I, Stanley M. Bergman, certify that:

1. I have reviewed this quarterly report on Form 10-Q of Henry Schein, Inc.;
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4. The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
  - (a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
  - (b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
  - (c) Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
  - (d) Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and
5. The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):
  - (a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
  - (b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Date: November 5, 2024

/s/ Stanley M. Bergman

Stanley M. Bergman  
Chairman and Chief Executive Officer

**CERTIFICATION PURSUANT TO RULE 13a-14(a) OR 15d-14(a) OF THE SECURITIES  
EXCHANGE ACT OF 1934, AS ADOPTED PURSUANT TO SECTION 302 OF THE  
SARBANES-OXLEY ACT OF 2002**

I, Ronald N. South, certify that:

1. I have reviewed this quarterly report on Form 10-Q of Henry Schein, Inc.;
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4. The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
  - (a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
  - (b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
  - (c) Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
  - (d) Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and
5. The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):
  - (a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
  - (b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Date: November 5, 2024

/s/ Ronald N. South

---

Ronald N. South  
Senior Vice President and  
Chief Financial Officer

**CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350,  
AS ADOPTED PURSUANT TO SECTION 906 OF THE  
SARBANES-OXLEY ACT OF 2002**

In connection with the quarterly report on Form 10-Q of Henry Schein, Inc. (the "Company") for the period ending September 28, 2024, as filed with the Securities and Exchange Commission on the date hereof (the "Report"), I, Stanley M. Bergman, the Chairman and Chief Executive Officer of the Company, and I, Ronald N. South, Senior Vice President and Chief Financial Officer of the Company, do hereby certify pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, to the best of my knowledge and belief that:

- (1) the Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and
- (2) the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Dated: November 5, 2024

/s/ Stanley M. Bergman

Stanley M. Bergman  
Chairman and Chief Executive Officer

Dated: November 5, 2024

/s/ Ronald N. South

Ronald N. South  
Senior Vice President and  
Chief Financial Officer

This certification accompanies each Report pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 and shall not, except to the extent required by the Sarbanes-Oxley Act of 2002, be deemed filed by the Company for purposes of Section 18 of the Securities Exchange Act of 1934, as amended.

A signed original of this written statement required by Section 906 of the Sarbanes-Oxley Act of 2002 has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.